Photoacoustic imaging compounds and methods of use
The development of xanthene-based imaging compounds with specific quenching moieties addresses the inefficiencies of current photoacoustic agents, enhancing image resolution and depth through efficient acoustic signal production.
Patent Information
- Application Number
- PCT/US2026/026730
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current photoacoustic imaging agents suffer from undesired aggregation, limited photostability, and lack of specific targets, leading to inefficient acoustic signal production and low resolution images due to high quantum yields.
Development of imaging compounds with a xanthene group substituted by aromatic or heteroaromatic quenching moieties, exhibiting a molar extinction coefficient of at least 50,000 M^-1cm^-1, quantum yield of less than 10%, and absorbance of 530 nm or greater, suitable for use in aqueous solutions for photoacoustic imaging.
The compounds provide high photoacoustic brightness with minimal fluorescence, enabling deeper tissue penetration and improved image resolution by efficiently converting absorbed light into acoustic signals.
Smart Images

Figure US2026026730_12112026_PF_FP_ABST
Abstract
Description
Docket No. TP388878WO1PHOTOACOUSTIC IMAGING COMPOUNDS AND METHODS OF USEFIELD OF INVENTION
[0001] Disclosed herein are imaging compounds, for example, substituted xanthene, rhodol, and rhodamine compounds, that are efficient quenchers of fluorescence and exhibit high photoacoustic brightness. Use of the compounds as photoacoustic imaging contrast agents and methods of making same are also described.BACKGROUND
[0002] Photoacoustic imaging (PAI) is an emerging hybrid imaging technology that combines the contrast and spectral nature of optics with the penetration depth and spatial resolution of acoustics. Contrast is based on optical absorption leading to thermoelastic expansion that creates pressure waves detectable with conventional transducers, and both endogenous absorbers (e.g., hemoglobin or melanin) and exogenous absorbers (e.g., ICG, methylene blue, or nanoparticles) have been used in this technique. Importantly, there is no bulk heating of tissue because short (~10 ns at ~5 Hz) light pulses are used with this technique. Photoacoustic imaging can generate a high-definition volumetric image of a tissue by measuring light-induced sound waves from an optically absorbing structure.
[0003] Photoacoustic imaging has gained popularity in the biomedical imaging field in the last two decades because it offers high-resolution imaging in deep biological tissues up to centimeter depths. Because sound scatters 1000 times less than light, the acoustic signal disseminates deeper into biological tissue than light without significant attenuation. As an example, photoacoustic imaging of the breast has garnered immense interest among researchers as an alternative to x-ray mammography due to the penetration depth it can achieve to cover most, if not the entire, breast and the prevalence of breast cancer. Photoacoustic imaging has also seen application in ex vivo, dermatologic, vascular, gastrointestinal, and musculoskeletal imaging.
[0004] While work in the field of photoacoustic imaging has been going on for over 20 years, no imaging agents specific for photoacoustic imaging have been developed and sold commercially. Rather, fluorogenic dyes, such as indocyanine green, ICG, and methylene blue, have been used as photoacoustic imaging contrast agents as these dyes are photoacoustically strong chromophores that are already FDA approved. Unfortunately, these conventionalDocket No. TP388878WO1contrast agents have several disadvantages when used in imaging workflows, i.e., undesired aggregation, limited photostability, and the absence of specific targets, which results in higher background signal.
[0005] Commercially available fluorescent dyes with high extinction coefficients, such as Alexa Fluor™ dyes from Thermo Fisher Scientific (Waltham, MA), have been repurposed as photoacoustic contrast agents. A significant drawback associated with using such commercially available dyes for photoacoustic imaging is that they have relatively high quantum yields. For example, Alexa Fluor™ 647 has a quantum yield (as measured in PBS buffer) of about 33%. Fluorescent dyes with high quantum yield can produce inefficient acoustic signal due to radiative loss of excitation energy and induction of a partial photoacoustic effect in the surrounding media. In the case of Alexa Fluor™ 647, 33% of the energy absorbed by the dye is emitted as fluorescence rather than acoustic signal. Inefficient production of acoustic signal by a high quantum yield dye can hinder sample penetration and contribute to production of a low resolution image. Thus, there is a need for compounds that can serve as effective contrast agents for use in photoacoustic imaging applications and do not suffer from the disadvantages associated with photoacoustic imaging contrast agents currently in use.BRIEF SUMMARY OF THE INVENTION
[0006] In one aspect, a photoacoustic imaging composition is described that includes:a) an aqueous solution; andb) an imaging compound, wherein the imaging compound includes a xanthene group, wherein the xanthene group comprises a nitrogen atom at the 3- and / or 6-position, wherein the nitrogen atom is substituted by one or more aromatic or heteroaromatic quenching moieties, Q, wherein the aqueous solution includes the imaging compound in a concentration suitable for detection in a photoacoustic imaging system, and wherein the compound exhibits an optical property selected from:i. a molar extinction coefficient of at least 50,000 M-1cm-1or greater;ii. a quantum yield of less than about 10%; andiii. absorbance of about 530 nm or greater, and a combination thereof.Docket No. TP388878WO1The aqueous solution can be, e.g., a buffer, saline, or a combination thereof. In certain embodiments, the aqueous solution can include about 1 μM to about 100 μM of the imaging compound.
[0007] In another aspect, a method of imaging a sample is described that includes: a) contacting the sample with a composition, as disclosed herein; b) exciting the compound with an energy source to produce an acoustic signal within the sample; and c) detecting the acoustic signal.
[0008] In yet another aspect, a method of imaging a sample is described that includes:a) contacting the sample with an imaging compound that includes a xanthene group, wherein the xanthene group includes a nitrogen atom at the 3- and / or 6-position, wherein the nitrogen atom is substituted by one or more quenching moieties, Q, wherein the compound exhibits an optical property selected from:i. a molar extinction coefficient of at least 50,000 M-1cm-1or greater;ii. a quantum yield of less than about 10%; andiii. absorbance of about 530 nm or greater, and a combination thereof;b) exciting the compound with an energy source to produce an acoustic signal within the sample; andc) detecting the acoustic signal.
[0009] The methods disclosed herein can further include irradiating the compound with an excitation light source to generate the acoustic signal and generating an image from the detected acoustic signal. Any of the methods described herein can be conducted in vivo or in vitro; and suitable samples for use in the disclosed methods include a cell or cell mimic, a blood or lymphatic vessel, a lymphatic node, a tissue or tissue mimic, artwork, a whole animal, or a human.
[0010] In certain embodiments, the disclosed compounds are used in a correlative imaging workflow comprising fluorescence detection and photoacoustic detection of the same sample, tissue, or subject. In certain embodiments, fluorescence detection is used to identify a region of interest, confirm delivery or retention of the compound, or corroborate localization observed byDocket No. TP388878WO1photoacoustic imaging. In certain embodiments, the fluorescence signal and the photoacoustic signal are acquired sequentially or substantially contemporaneously.
[0011] In yet another aspect, compositions and methods are disclosed that include a compound that exhibits minimal or substantially no detectable fluorescence when excited by the energy source. The absorbance of the compound can be about 650 nm or greater. For example, the absorbance maximum of the compound can be about 650 nm to about 900 nm. The quantum yield of the compound can be less than about 3%. The molar extinction coefficient of the compound can be about 50,000 M-1cm-1to about 10,000,000 M-1cm_1. In certain embodiments, the imaging compound is conjugated to a substance, wherein the conjugated substance (Sc) is a biologically derived material such as a cell, tissue vessel, node, bone, and tumor. In certain embodiments, the conjugated substance (Sc) is a cell-targeting peptide, an antibody, or an antigen. In other embodiments, the conjugated substance (Sc) is a non-biologically derived material (e.g., cell, tissue mimic, or a solid support such as a magnetic bead or a polystyrene support).
[0012] In certain embodiments, the disclosed compounds are further characterized by one or more fluorescence properties, including excitation spectrum, emission spectrum, fluorescence intensity, quantum yield, brightness, Stokes shift, fluorescence lifetime, photostability, or combinations thereof. In certain embodiments, the compounds, while configured for photoacoustic imaging, exhibit measurable fluorescence under selected excitation and emission conditions. Such fluorescence may be used to characterize the compound, confirm compound presence, delivery, localization, or retention, or corroborate compound localization.
[0013] Imaging compounds disclosed herein can be a substituted rhodol or substituted rhodamine, as disclosed herein. For example, the compound can be selected from Table 4. In certain embodiments, the imaging compound has the formula:Docket No. TP388878WO1R1is H; R6is H;R2, R3, R4and R5are independently H, F, Cl, Br, I, CN; or Ci-Cis alkyl, or Ci-Cis alkoxy,where each alkyl or alkoxy is optionally further substituted by F, Cl, Br, I, a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alcohol; or — SO3Xwhere X is H or a counterion;or R1taken in combination with R2, or R6taken in combination with R5is a fused six-membered aromatic ring;R8and R9are independently H, Ci-Ce alkyl, Ci-Ce carboxyalkyl, Ci-Ce sulfoalkyl, a salt of C1-C6 carboxyalkyl, or a salt of Ci-Ce sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl; or — L — Rx; or — L — Sc; or one or more of R8and R9is a Q moiety; or R8taken in combination with R9forms a saturated 5- or 6-membered heterocycle that is optionally fused to a Q moiety and said heterocycle is optionally further substituted by methyl, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce alkyl, or by — L — Rx, or — L — Sc,Docket No. TP388878WO1wherein each Q moiety is 1-4 aromatic or heteroaromatic rings that is optionally substituted by halogen, cyano, sulfo, alkali or ammonium salt of sulfo, carboxy, alkali or ammonium salt of carboxy, nitro, alkyl, perfluoroalkyl, alkoxy, alkylthio, amino, monoalkylamino, dialkylamino; alkylamido; or is substituted by — L — Rx; or is substituted by — L — Sc; wherein each heteroaromatic ring in Q is a 5- or 6-membered aromatic heterocycle having 1 to 3 heteroatoms selected from the group consisting of O, N or S in any combination; and when Q is 2-4 rings, said 2-4 rings are fused to each other; andK is O or N+R18R19;wherein R18and R19are independently H, Ci-Ce alkyl, Ci-Ce carboxyalkyl, C1-C6sulfoalkyl, a salt of Ci-Ce carboxyalkyl, or a salt of Ci-Ce sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl; or — L — Rx; or — L — Sc; or one or more of R18and R19is a Q moiety; or R18taken in combination with R19forms a saturated heterocyclic ring that is a morpholine, a pyrazine, or a piperazine, that is optionally substituted by methyl, sulfonic acid, a salt of sulfonic acid, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl; or R18taken in combination with R19forms a saturated 5- or 6-membered heterocycle that is a piperidine, or a pyrrolidine that is optionally fused to a Q moiety, and the heterocycle is optionally further substituted by methyl, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce alkyl, or by — L — Rx, or — L — Sc;R10is H, CN, a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alcohol; or R10is a saturated or unsaturated Ci-Cis alkyl that is optionally substituted one or more times by F, Cl, Br, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce alcohol, — SO3X, amino, alkylamino, or dialkylamino, the alkyl groups of which have 1-6 carbons; or R10has the formulaDocket No. TP388878WO1where R12, R13, R14, R15and R16are independently H, F, Cl, Br, I, — SO3X, a carboxylic acid, a salt of carboxylic acid, CN, hydroxy, amino, hydrazino; or Ci-Cis alkyl, Ci-Cis alkoxy, Ci-Cis alkylthio, Ci-Cis alkanoylamino, Ci-Cis alkylaminocarbonyl, C2-C36 dialkylaminocarbonyl, Ci-Cis alkyloxycarbonyl, or Ce-Cis arylcarboxamido, the alkyl or aryl portions of which are optionally substituted one or more times by F, Cl, Br, T, hydroxy, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce alcohol, — SO3X, amino, alkylamino, dialkylamino or alkoxy, the alkyl portions of each having 1-6 carbons; or one pair of adjacent substituents R13and R14, R14and R15or R15and R16, when taken in combination, form a fused 6-membered aromatic ring that is optionally further substituted by carboxylic acid, or a salt of carboxylic acid; or one of R12, R13, R14, R15and R16is — L — Rxor — L— Sc;provided that at least one of R8, R9, R18, and R19is, or is fused to, a Q moiety; andfurther provided that at least one of R8, R9, R12, R13, R14, R15. R16, R18, or R19is — L — Rxor — L — Sc; or at least one Q moiety is substituted by — L — Rxor — L — Sc; whereinL is a covalent linkage; andRxis a reactive functional group that is a maleimide, isocyanate, isothiocyanate, a phosphoramidite, a reactive platinum complex, perfluorobenzamido, azidoperfluorobenzamido, a succinimidyl ester, a sulfosuccinimidyl ester, an alkali or alkaline earth metal salt of a sulfosuccinimidyl ester, a symmetric anhydride, a mixed anhydride of a chloroformate having 2-8 carbons, a mixed anhydride of a carboxylic acid or perfluorinated carboxylic acid having 2-Docket No. TP388878WO18 carbons, a mixed anhydride of a sulfonic acid or fluorinated sulfonic acid having 1-8 carbons, or an ester of a phenol or a naphthol that is further substituted one or more times by nitro, sulfo, carboxy, alkali or alkaline earth metal salt of sulfo or carboxy, cyano, fluoro, chloro, or trifluoromethyl; or Rxis the adduct of a carboxylic acid and a carbodiimide having 2-14 carbons; and Scis a conjugated substance. In specific embodiments, each Q moiety can be a substituted or unsubstituted phenyl, naphthyl, anthracenyl, benzothiazole, benzoxazole, benzimidazole, indoline or substituted indoline. In other independent embodiments, K is N+R18R19; R8taken in combination with R9forms a saturated 5- or 6-membered heterocycle that is fused to a Q moiety, and R18taken in combination with R19forms a saturated 5- or 6-membered heterocycle that is fused to a Q moiety; RX=R19and R9=R18; and / or R1, R2, R5, and R6are each H. In certain embodiments, R10has the formula:In independent embodiments, one of R12-R16is — L — Rxor — L — Sc; 30; R12is — L — Rx; and L is selected such that — L — Rxhas the formula:Docket No. TP388878WO1In any of the compounds disclosed herein, Rxcan a succinimidyl ester of a carboxylic acid, a haloacetamide, a hydrazine, an isothiocyanate, a maleimide group or an azidoperfluorobenzamido group.In yet another embodiment, compounds are described having the formula:Docket No. TP388878WO1whereinR8=R19and R9=R18;R12is — L — Rx, or — L — Sc; andeach Q moiety is a substituted or unsubstituted phenyl, naphthyl, anthracenyl, berzothiazole, benzoxazole, or benzimidazole.
[0014] In yet another aspect, a kit for photoacoustic imaging of a sample is disclosed that includes:a) the composition or compound, as disclosed herein; andb) instructions for using the composition or compounds for photoacoustic imaging of the sample.Docket No. TP388878WO1
[0015] In certain embodiments, the kit further comprises a sterile diluent, wash solution, buffer, control composition, comparator probe, second photoacoustic probe, administration device, calibration standard, image-analysis instructions, or combinations thereof. In certain embodiments, the instructions are for imaging cartilage, imaging a joint comprising cartilage, differentiating cartilage from bone or non-cartilaginous tissue, assessing cartilage condition, performing serial imaging, or performing multiplex imaging with a second probe.
[0016] In certain embodiments, the imaging compound is configured to preferentially associate with cartilage. Cartilage targeting can be achieved by incorporating one or more cationic moieties, such as a quaternary ammonium group, into the imaging compound or into a substituent attached thereto.
[0017] Without wishing to be bound by theory, the cationic moiety can electrostatically associate with anionic components of cartilage, including glycosaminoglycans and proteoglycans, thereby increasing the local concentration of the imaging compound in cartilage relative to adjacent non-cartilaginous tissue.
[0018] In some embodiments, the preferential association with cartilage persists after washing or clearance of unassociated compound, thereby improving cartilage-to-background contrast in photoacoustic imaging.
[0019] In some embodiments, the cartilage comprises articular cartilage, fibrocartilage, meniscal cartilage, tracheal cartilage, auricular cartilage, costal cartilage, intervertebral disc cartilage, growth plate cartilage, or a combination thereof.
[0020] In some embodiments, the methods described herein are used to visualize cartilage integrity, cartilage degeneration, cartilage thinning, a cartilage defect, a cartilage lesion, or combinations thereof.
[0021] In certain embodiments, the methods described herein are used to detect, visualize, map, segment, quantify, classify, or monitor cartilage distribution, cartilage thickness, cartilage volume, cartilage repair tissue, osteochondral interfaces, cartilage fissures, delamination, calcification, degeneration-associated changes, inflammation-associated changes, or combinations thereof. In certain embodiments, the methods are used for diagnosis, prognosis, subject stratification, treatment planning, intraoperative guidance, arthroscopy, post-procedural monitoring, monitoring of disease progression, or assessment of response to therapy. Nonlimiting indications include osteoarthritis, post-traumatic cartilage injury, osteochondralDocket No. TP388878WO1defects, meniscal injury, rheumatoid arthritis, degenerative disc disease, chondral lesions, and cartilage repair procedures.
[0022] The compositions described herein are not limited to topical application and may be administered to a sample or subject by injection.
[0023] In certain embodiments, the cartilage-targeting moiety is incorporated directly into the imaging compound, into a substituent attached thereto, into a quenching moiety Q, or into a conjugated substance Sc attached through a covalent linkage L. In certain embodiments, one or more of R8, R9, R12, R13, R14, R15, R16, R18, or R19, or a substituent on Q, comprises or is substituted by a cartilage-targeting moiety. In certain embodiments, exactly one cartilagetargeting moiety is present. In other embodiments, the imaging compound comprises two or more cartilage-targeting moieties.
[0024] In certain embodiments, the cartilage-targeting moiety is present as a conjugated substance (Sc) attached to the imaging compound through a covalent linkage (L). Thus, in some embodiments, one of R12-R16, optionally R12, R14, or R15, is — L — Sc, wherein Sc comprises a cartilage-targeting moiety. In certain embodiments, Sc comprises a cationic cartilagetargeting moiety, such as a quaternary ammonium-containing cartilage-targeting moiety, that confers preferential association or localization of the imaging compound to cartilage, including articular cartilage, relative to bone or non-cartilaginous soft tissue after contacting a biological sample or after administration to a sample or subject. In certain embodiments, the preferential association persists after washing or clearance of unassociated compound, thereby permitting photoacoustic detection and imaging of cartilage and assessment of cartilage integrity, cartilage degeneration, cartilage thinning, cartilage defects, cartilage lesions, or combinations thereof.
[0025] In certain embodiments, the cartilage-targeting moiety comprises a quaternary ammonium-containing group attached through a linker to the imaging compound, optionally through Sc. In certain embodiments, the quaternary ammonium-containing group comprises a trialkylammonium group, a hydroxyalkyl trialkylammonium group, or a cyclic quaternary ammonium group. In certain embodiments, the quaternary ammonium-containing group is attached through an alkylene linker, an amide-containing linker, a sulfonamide-containing linker, a carbamate-containing linker, a urea-containing linker, or combinations thereof. In certain embodiments, the linker between the imaging compound and the cationic nitrogen comprises from 2 to 8 carbon atoms. In certain embodiments, the imaging compound comprises one quaternary ammonium-containing cartilage-targeting moiety. In other embodiments, theDocket No. TP388878WO1imaging compound comprises two quaternary ammonium-containing cartilage-targeting moieties.
[0026] Additional embodiments and advantages will be set forth in part in the description which follows, and in part will be understood from the description, or may be learned by practice. The objects and advantages will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
[0027] In certain embodiments, localization of the imaging compound in tissue is depicted schematically in figures using shading, stippling, or hatching to represent regions of retained compound.
[0028] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claims.BRIEF DESCRIPTION OF THE DRAWINGS
[0029] The accompanying drawings are provided to illustrate certain embodiments of the present disclosure and are not intended to limit the scope of the invention. The drawings may not be to scale, and various features may be exaggerated or simplified for clarity. In certain figures, tissue features and localization of imaging compounds are represented schematically using shading, stippling, hatching, cross-hatching, or other graphical patterns rather than color. Such representations are used to distinguish regions of retained imaging compound from surrounding tissue and are not intended to depict actual color, intensity, or quantitative signal.
[0030] FIG. 1 is a schematic illustration of an exemplary ex vivo cartilage-targeted photoacoustic imaging workflow, including contacting a cartilage-containing tissue sample with an imaging compound, washing to remove unassociated compound, and performing photoacoustic imaging. Shaded or patterned regions indicate locations of retained imaging compound and resulting photoacoustic signal.
[0031] FIG. 2A illustrates representative schematic depictions of a control ex vivo tissue specimen comprising cartilage and bone following incubation and washing, wherein minimal or no patterned regions are observed at cartilage-containing locations.
[0032] FIG. 2B illustrates representative schematic depictions of an ex vivo tissue specimen comprising cartilage and bone after contact with a cartilage-targeted imaging compound and washing, wherein patterned regions indicate retained localization at cartilage-containing regions.Docket No. TP388878WO1
[0033] FIG. 3 illustrates representative comparative schematic depictions of control and treated ex vivo tissue specimens comprising cartilage and bone, wherein increased shading or patterning in the treated specimen indicates preferential localization of the imaging compound to cartilage-containing regions.DETAILED DESCRIPTION
[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of microscopy, biochemistry, molecular biology, immunology, microbiology, genetics, cell and tissue culture, and protein and nucleic acid chemistry described herein are well known and commonly used in the art. In case of conflict, the present disclosure, including definitions, will control. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the embodiments and aspects described herein.
[0035] As used herein, terms such as “include.” “including,” “contain,” “containing,” “having,” and the like mean “comprising.” The present disclosure also contemplates other embodiments “comprising,” “consisting essentially of,” and “consisting of’ the embodiments or elements presented herein, whether explicitly set forth or not. As used herein, “comprising,” is an “open-ended” term that does not exclude additional, unrecited elements or method steps. As used herein, “consisting essentially of’ limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. As used herein, “consisting of’ excludes any element, step, or ingredient not specified in the claim.
[0036] As used herein, the term “a,” “an,” “the” and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In addition, “a,” “an,” or “the” means “one or more” unless otherwise specified. As used herein, the term “or” can be conjunctive or disjunctive. As used herein, the term “and / or” refers to both the conjunctive and disjunctive. As used herein, the term “substantially” means to a great or significant extent, but not completely.Docket No. TP388878WO1
[0037] As used herein, the term “about” or “approximately” as applied to one or more values of interest, refers to a value that is similar to a stated reference value, or within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, such as the limitations of the measurement system. In one aspect, the term “about” refers to any values, including both integers and fractional components that are within a variation of up to ± 10% of the value modified by the term “about.” Alternatively, “about” can mean within 3 or more standard deviations, per the practice in the art. Alternatively, such as with respect to biological systems or processes, the term “about” can mean within an order of magnitude, in some embodiments within 5-fold, and in some embodiments within 2-fold, of a value. As used herein, the symbol means “about” or “approximately.”
[0038] As used herein, the term “dye” refers broadly to a compound that absorbs electromagnetic radiation and may emit energy in the form of light, heat, or acoustic signal. Accordingly, the term “dye” includes compounds used for optical imaging, fluorescence imaging, photoacoustic imaging, or combinations thereof. In certain embodiments, dyes as described herein function as photoacoustic imaging compounds or contrast agents, regardless of whether the compound exhibits fluorescence.
[0039] Unless otherwise specified, references to “dye,” “imaging compound,” or “contrast agent” may be used interchangeably in the context of the present disclosure.
[0040] As used herein, terms such as “staining,” “color,” “colored,” or similar expressions refer broadly to the presence, localization, or retention of an imaging compound in a sample or tissue and do not require the presence of visible color. Such staining or color may be detected visually, instrumentally, or schematically, including by photoacoustic signal, fluorescence, or other imaging modalities.
[0041] As used herein, references to “localization,” “signal,” or “retention” of an imaging compound may be determined by visual inspection, schematic representation, or instrumentbased detection, including photoacoustic detection. In the figures, tissue features and localization of imaging compounds may be represented schematically using shading, stippling, hatching, cross-hatching, patterning, or combinations thereof rather than color. Such graphical representations are used to distinguish regions of retained imaging compound from surrounding tissue and are not intended to represent actual color, intensity, or quantitative signal. RegionsDocket No. TP388878WO1depicted with increased shading, stippling, or hatching generally correspond to regions in which the imaging compound is retained or preferentially localized.
[0042] As used herein, “cartilage-targeting moiety” refers to a substituent, conjugated substance, or portion of an imaging compound that confers preferential association or localization of the imaging compound to cartilage, optionally articular cartilage, relative to bone or non-cartilaginous soft tissue after contacting a biological sample or after administration to a sample or subject. In certain embodiments, the cartilage-targeting moiety comprises a cationic moiety, such as a quaternary ammonium-containing moiety.
[0043] As used herein, “preferentially associates” or “preferentially localizes” means that the imaging compound is present, retained, or detected at a higher level in cartilage than in a comparator tissue, such as bone or non-cartilaginous soft tissue, under comparable contacting, administration, washing, clearance, or imaging conditions.
[0044] All ranges disclosed herein include both end points as discrete values as well as all integers and fractions specified within the range. For example, a range of 0.1-2.0 includes 0.1, 0.2, 0.3, 0.4... 2.0. If the end points are modified by the term “about,” the range specified is expanded by a variation of up to ±10% of any value within the range or within 3 or more standard deviations, including the end points, or as described above in the definition of “about.”
[0045] Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this disclosure and have the following meaning:
[0046] As used herein, “hydrophilic group” refers to a substituent that increases the solubility of the compounds in aqueous solution. Exemplary hydrophilic groups include but are not limited to -OH, -O Z+, -SH, -S Z+, -NH2, -NR3+Z‘, -N=NR2+Z", -CN, -OCN, -SCN, -NCO, -NCS, -NO, -NO2, -N2+, -N3, -NHC(O)R, -C(O)R, -C(O)NR2, -S(O)2Q-Z+, -S(O)2R, -OS(O)2OR, -S(O)2NR, -S(O)R, -OP(O)(OR)2. -P(O)(OR)2, -P(O)(O )2Z+, -P(O)(OH)2, -C(O)R, -C(S)R, -C(O)OH, -C(O)OR, -CO2Z+, -C(S)OR, -C(S)O Z+, -C(O)SR, -C(O)S Z+, -C(S)SR, -C(S)S Z+, -C(O)NR2, -C(S)NR2, -C(NR)NR2, where R is H, Ci-Ce alkyl, Ci-Ce alkylCe-Cio aryl, or Ce-Cio aryl, and optionally substituted, polyethylene glycol, and the like.
[0047] The term “photoacoustic contrast agent,” as used herein, refers to a compound that emits an acoustic signal upon absorption of light at an appropriate wavelength. A photoacoustic contrast agent can display a photoacoustic effect, i.e., a conversion of pulsed light of an appropriate wavelength into ultrasound waves.Docket No. TP388878WO1
[0048] As used herein, “water-solubilizing group” refers to a moiety that increases the solubility of the compounds in aqueous solution. Exemplary water-solubilizing groups include but are not limited to hydrophilic group, as described herein, polyether, polyhydroxyl, boronate, polyethylene glycol, repeating units of ethylene oxide (-(CH2CH2O)-), and the like.
[0049] As used herein, “cartilage-targeting moiety” refers to a substituent, conjugated substance, ligand, ionic group, or combination thereof that confers preferential association, localization, retention, adsorption, partitioning, or accumulation of an imaging compound in cartilage, a cartilage-containing region, or cartilage extracellular matrix relative to bone or non-cartilaginous tissue under comparable contacting, administration, washing, clearance, or imaging conditions. In certain embodiments, the cartilage-targeting moiety comprises one or more cationic centers at physiological pH. In certain embodiments, the cartilage-targeting moiety comprises a permanently cationic group or a protonatable group. Non-limiting examples include quaternary ammonium, protonated amine, amidinium, guanidinium, pyridinium, imidazolium, phosphonium, sulfonium, or combinations thereof.
[0050] As used herein, “preferentially associates” or “preferentially localizes” means that the imaging compound is present, retained, or detected in cartilage at a level greater than in a comparator tissue under comparable contacting, administration, washing, clearance, or imaging conditions. In certain embodiments, the comparator tissue comprises bone, synovium, muscle, fat, tendon, ligament, capsule, marrow, or other non-cartilaginous soft tissue. Preferential association or localization may be determined qualitatively, quantitatively, or both.
[0051] In the figures, tissue features and localization of imaging compounds may be represented schematically using shading, stippling, hatching, cross-hatching, patterning, or combinations thereof. Such graphical representations are used to distinguish regions of retained imaging compound from surrounding tissue and are not intended to represent actual color, intensity, or quantitative signal. Regions depicted with increased shading, stippling, or hatching generally correspond to regions in which the imaging compound is retained or preferentially localized.
[0052] The compounds disclosed herein may exist in unsolvated forms as well as solvated forms, including hydrated forms. In some embodiments, the compounds disclosed herein are soluble in an aqueous medium (e.g., water or a buffer). For example, the compounds can include substituents (e.g., water-solubilizing groups) that render the compound soluble in the aqueous medium. Compounds that are soluble in an aqueous medium are referred to herein asDocket No. TP388878WO1“water-soluble” compounds. Such water-soluble compounds are particularly useful in biological assays. These compounds may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses described herein and are intended to be within the scope of the present disclosure. The compounds disclosed herein may possess asymmetric carbon atoms (z.e., chiral centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers of the compounds described herein are within the scope of the present disclosure. The compounds described herein may be prepared as a single isomer or as a mixture of isomers.
[0053] Where substituent groups are specified by their conventional chemical formulae and are written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, e.g., -CH2O- will be understood to also recite -OCH2-.
[0054] It will be understood that the chemical structures that are used to define the compounds disclosed herein are each representations of one of the possible resonance structures by which each given structure can be represented. Further, it will be understood that by definition, resonance structures are merely a graphical representation used by those of skill in the art to represent electron delocalization, and that the present disclosure is not limited in any way by showing one particular resonance structure for any given structure.
[0055] Where a disclosed compound includes a conjugated ring system, resonance stabilization may permit a formal electronic charge to be distributed over the entire molecule. While a particular charge may be depicted as localized on a particular ring system, or a particular heteroatom, it is commonly understood that a comparable resonance structure can be drawn in which the charge may be formally localized on an alternative portion of the compound.
[0056] The above-defined groups may include prefixes and / or suffixes that are commonly used in the art to create additional well-recognized substituent groups. As non-limiting specific examples, “alkyloxy” and / or “alkoxy” refer to a group of the formula -OR”, “alkylamine” refers to a group of the formula -NHR” and “dialkylamine” refers to a group of the formula -NR”R”, where each R” is an alkyl.
[0057] Compounds are described for use as contrast agents for photoacoustic imaging (PAI) applications. In general, the instant compounds are characterized by their broad absorption spectrum, high quantum yield, and exceptional photo stability that can facilitate photoacousticDocket No. TP388878WO1imaging of samples with high resolution. The compounds of the present disclosure can be designed to enhance light absorption and energy conversion efficiency that can lead to significant improvements in their photoacoustic response, making them well-suited for use in applications ranging from tumor detection to environmental sensing.
[0058] Thus, provided herein are compounds that absorb energy in the visible to near-IR spectral region and exhibit a high molar extinction coefficient (i.e., molar absorption coefficient) and low quantum yield. In certain embodiments, it can be advantageous that the compound exhibit a broad and strong absorption spectrum, especially in the near-infrared region for deeper tissue penetration.
[0059] Exemplary compounds for use as PAI contrast agents include compounds that can be excited with light but exhibit little or no observable fluorescence. As used herein, the term “dye” refers to a compound that absorbs light or radiation and may or may not emit light. A “fluorescent dye” refers to a molecule that emits the absorbed light to produce an observable detectable signal. In some embodiments, compounds are provided that absorb light with a wavelength in the visible to near-IR spectral region and emit acoustic signal with minimal or substantially no detectable fluorescence.
[0060] Although the disclosed compounds are configured for efficient photoacoustic signal generation and may exhibit minimal or substantially no detectable fluorescence under conditions used for photoacoustic imaging, the compounds may nevertheless exhibit detectable fluorescence under selected excitation and emission conditions. In certain embodiments, such fluorescence is useful as an auxiliary readout for compound characterization, assay development, confirmation of compound localization, evaluation of tissue association, assessment of wash resistance or retention, or correlation with photoacoustic signal. In certain embodiments, fluorescence measurements are obtained in solution, in a solid matrix, in a tissue mimic, in excised tissue, or in biological tissue, and may include one or more of excitation spectrum, emission spectrum, fluorescence intensity, brightness, quantum yield, fluorescence lifetime, or photostability.
[0061] The degree to which a compound can absorb and emit light can be determined by measuring the quantum yield (QY) of the compound. The quantum yield for PAI applications can be measured in a solid matrix, such as when embedded in a tissue sample or tissue mimic or in solution. Compounds that are particularly suitable for use as a PAI contrast agent include those that display quantum yield when measured in a solid matrix of less than about 10% (atDocket No. TP388878WO1which point certain compounds can still be dimly fluorescent). When used in photoacoustic imaging, a compound that exhibits a QY of -10% will theoretically lose -10% or less of its acoustic signal s. Compounds that are particularly suitable for use as a PAI contrast agent include those that display quantum yields of less than about 5%; or less than 4%; or less than 3%; or less than 2%; or less than 1%. In certain embodiments, the imaging agent exhibits a quantum yield of less than about 0.05.
[0062] Compounds are disclosed that produce a large acoustic signal. As used herein, a compound exhibiting a large acoustic signal can be characterized as having a high “photoacoustic brightness.” Compounds with high photoacoustic brightness typically exhibit a molar extinction coefficient of at least 50,000 M^cm’1. For example, compounds disclosed herein can exhibit a molar extinction coefficient of about 50,000 M'1to about 10,000,000 M^cnr1; or about 50,000 M-1cm_1to about 5,000,000 M-1cm1; orabout 50,000 NT'crrr1to about 1,000,000 M-'cm.
[0063] Imaging compounds for imaging applications, as disclosed herein, can absorb light in the visible to near-IR portion electromagnetic spectrum and exhibit little or no observable fluorescence. Although not required, it can be advantageous for PAI imaging applications that the absorbance maximum of the contrast agent be about 530 nm or greater. In certain embodiments, the compounds absorb energy between about 530 nm to about 900 nm.
[0064] Provided herein are imaging compounds that can exhibit one or more optical properties selected from:a. a molar extinction coefficient of at least 50,000 VT'CITT1or greater;b. a quantum yield of less than about 10%; andc. absorbance of about 530 nm or greater.
[0065] For photoacoustic imaging applications, suitable imaging compounds should be thermally and photolytically stable, such that they can withstand pulsed laser irradiation without significant loss of photophysical properties. Compounds that are stable under prolonged light exposure are desirable to ensure consistent performance. Compounds disclosed herein that are biocompatible (e.g., compatible with living tissue and are non-toxic) are particularly well-suited for medical applications (e.g., injection into a subject in vivo).Docket No. TP388878WO1
[0066] The imaging compounds disclosed herein offer a unique combination of optical and physical properties that make them ideal for use in photoacoustic imaging applications. The compounds can exhibit high extinction coefficients in the visible to near-IR spectral region, where tissue absorption is low, low quantum yields (i.e., minimal fluorescence), fast clearance from non-target sites, and limited toxicity. Further, compounds disclosed herein exhibit favorable relaxation effects that result in production of increased ultrasound signal as compared to other types of fluorescent dyes under the same irradiation conditions. Increased ultrasound signal can contribute to deeper penetration through tissue and the production of high-resolution images as compared to other types of fluorescent contrast agents that are currently in use.
[0067] The imaging compounds of the present disclosure can be designed to maximize their efficacy as contrast agents in photoacoustic assays. For example, compounds can be designed to provide a combination of efficient energy absorbance with dampened fluorescence emission, e.g., by introduction of groups that contribute to quenching of fluorescence. For example, it was found that incorporation of a group(s) into the compound that can localize electrons in certain regions of the compound can affect the extent of fluorescence quenching exhibited by the compound. Localization of electrons in certain types of nitrogen-containing groups (e.g., azo, azide, nitro groups and the like) can significantly quench the fluorescence of the compound. Without wishing to be bound by theory, such quenching is thought to be a result of intramolecular charge transfer. Rather than emitting a fluorescence signal, compounds including one or more electron localization groups can emit the absorbed energy as an acoustic wave, making such compounds particularly suitable for use as PAI contrast agents.
[0068] Thus, provided herein are compounds that display a quantum yield of less than 10% that include quenching group or a combination of a quenching groups (e.g., an azo, azide, N-phenyl or nitro group).
[0069] Various types of compounds are disclosed herein that can be suitable for use in photoacoustic imaging applications. A representative class of compounds for use in photoacoustic imaging includes nitrogen-substituted xanthenes that are substituted by one or more aromatic or hetero aromatic quenching moieties, e.g., derivatives of 3 and / or 6-amino xanthenes that are substituted at one or more amino nitrogen atoms by an aromatic or heteroaromatic quenching moiety, Q. In certain embodiments, the substituted xanthene can be a rhodamine or rhodol substituted with a quenching moiety, Q.Docket No. TP388878WO1
[0070] As used herein, Q is an aromatic or heteroaromatic ring system, having 1-4 fused aromatic or heteroaromatic rings, attached to the amino nitrogen by a single covalent bond. Where the Q moiety is fully aromatic and contains no heteroatom, Q comprises 1-4 fused six membered aromatic rings. Where the Q moiety is heteroaromatic, Q incorporates at least one 5-or 6-membered aromatic heterocycle that contains at least 1 and as many as 4 heteroatoms that are selected from the group consisting of O, N, and S in any combination, that is optionally fused to an additional six-membered aromatic ring, or is fused to one 5- or 6-membered heteroaromatic ring that contains at least 1 and as many as 3 heteroatoms that are selected from the group consisting of O, N, and S in any combination.
[0071] Each Q moiety is bound to the xanthene compound at a 3- or 6-amino nitrogen atom via a single covalent bond. In some embodiments, the amino nitrogen substituents, taken in combination, form a 5- or 6-membered heterocycle that is a piperidine, a morpholine, a pyrrolidine, a pyrazine, or a piperazine, and the Q moiety is fused to the resulting heterocycle adjacent to the xanthene nitrogen, so as to be formally bound to the amino nitrogen via single bond. The Q moiety may be bound to the amino nitrogen atom at either an aromatic or heteroaromatic ring, provided it is attached at a carbon atom of that ring.
[0072] Typically, the Q moieties are substituted or unsubstituted phenyl, naphthyl, anthracenyl, benzothiazole, benzoxazole, or benzimidazole. Where the amino nitrogen substituents form a 5- or 6-membered heterocycle and the Q moiety is fused to the resulting heterocycle, the heterocycle is typically a pyrrolidine ring and the Q moiety is typically a fused six-membered aromatic ring. Most preferably, Q is an indoline or substituted indoline.
[0073] Each Q moiety is optionally and independently substituted by hydrogen, halogen, cyano, sulfo, alkali or ammonium salt of sulfo, carboxy, alkali or ammonium Salt of carboxy, nitro, alkyl, perfluoroalkyl, alkoxy, alkylthio, amino, monoalkylamino, dialkylamino or alkylamido.
[0074] A class of compounds for use in photoacoustic applications can have the formulaDocket No. TP388878WO1wherein the K moiety is O or N+R18R19.
[0075] For all the disclosed compounds, at least one of R8, R9, R18and R19is a Q moiety. Alternatively, either R8taken in combination with R9, or R18taken in combination with R19, forms a saturated 5- or 6-membered heterocycle that is a piperidine, or a pyrrolidine that is fused to a Q moiety. Typically one of R8and R9and one of R18and R19are each a Q moiety, which are the Same or different. In another embodiment, each of R8, R9, R18and R19is a Q moiety, which may be the same or different.
[0076] The remainder of R8, R9, R18and R19are independently H, Ci-Ce alkyl, Ci-Ce carboxyalkyl, Ci-Ce sulfoalkyl, a salt of Ci-Ce carboxyalkyl, or a salt of Ci-Ce sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a Salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl. Alternatively, where R8in combination with R9, or R18in combination with R19, or both, forms a saturated 5- or 6-membered heterocyclic ring that is a piperidine, a morpholine, a pyrrolidine, a pyrazine, or a piperazine, that is optionally substituted by methyl, sulfonic acid, a salt of sulfonic acid, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl.Alternatively, one or more of R8in combination with R2, R9in combination with R3, R18in combination with R4, or R19in combination with R5, forms a 5- or 6-membered ring that is Saturated or unsaturated, and that is optionally Substituted by one or more Ci-Ce alkyls or -CHSO3X, where X is H or a counterion.
[0077] R1and R6are H, or one or more of R1in combination with R2, or R6in combination with R5, is a fused six-membered aromatic ring.
[0078] Substituents R2, R3, R4, and R5are independently H, F, Cl, Br, I, CN; or Ci-Cis alkyl, or Ci-Cis alkoxy, where each alkyl or alkoxy is optionally further substituted by F, Cl, Br, I, a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alcohol; polyethylene glycol, or -SO3X.
[0079] The pendant group R10is H, CN, a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce, alcohol. Alternatively, R10is a saturated or unsaturated, branched or unbranched Ci-Cis alkyl that is optionally substituted one or more times by F, Cl, Br, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce, alcohol, -SO3X, amino, alkylamino, or dialkylamino, the alkyl groups of which have 1-6 carbons. In another preferred embodiment, R10has the formulaDocket No. TP388878WO1
[0080] where R12, R13, R14, R15and R16are independently H, F, Cl, Br, I, -SO3X, a carboxylic acid, a salt of carboxylic acid, CN, hydroxy, amino, hydrazino, azido, or Ci-Cis alkyl, Ci-Cis alkoxy, Ci-Cis alkylthio, Ci-Cis alkanoylamino, Ci-Cis alkylaminocarbonyl, C2-C36 dialkylaminocarbonyl, Ci-Cis alkyloxycarbonyl, or C7-C18 arylcarboxamido, the alkyl or aryl portions of which are optionally Substituted one or more times by F, Cl, Br, I, hydroxy, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a C1-C6, alcohol, -SO3X, amino, alkylamino, dialkylamino or alkoxy, the alkyl portions of each having 1-6 carbons. Alternatively, a pair of adjacent substituents R13and R14, R14and R15, or R15and R16, taken in combination, form a fused 6-membered aromatic ring that is optionally further Substituted by carboxylic acid, or a Salt of carboxylic acid.
[0081] The compounds can be optionally substituted by a reactive group (Rx) or conjugated substance (Sc) that is attached to the compound by a covalent linkage, L. Typically, the instant compound is substituted by an -L-Rx, or -L-Scmoiety at one or more of R8, R9, R12, R13, R14. R15, R16, R18, or R19, preferably at one of R12-R16, most preferably at R12, R14or R15, or as a substituent on a Q moiety. Alternatively, an -L-Rx, or -L-Scmoiety is present as a substituent on an alkyl, alkoxy, alkylthio or alkylamino Substituent. In one embodiment, exactly one of R8, R9, R12, R13, R14, R15, R16, R18, or R19, is an -L-Rx, or -L-Scmoiety. In another embodiment, exactly one of R12, R13, R14, R15, or R16is an -L-Rx, or -L-Scmoiety. In a preferred embodiment, one of R12, R14, and R15is an -L-Rx, or -L-Scmoiety.
[0082] Where the K moiety is N+R18R19, the compounds are rhodamines, and have the formulaDocket No. TP388878WO1wherein at least one of R8. R9, R18and R19is a Q moiety. Preferably at least one of R8and R9is a Q moiety and at least one of R18and R19is a Q moiety, which may be the same or different.
[0083] In certain embodiments, the rhodamine is 5- or 6-carboxytetramethylrhodamine, or a reactive version thereof, such 5-TAMRA, SE (5 -carboxy tetramethylrhodamine, succinimidyl ester from Thermo Fisher Scientific).
[0084] Where the K moiety is O, the compounds of the present disclosure are rhodols. and have the formulawherein at least one of R8and R9is a Q moiety.
[0085] Generally colorless forms of the instant compounds have the formulawherein J is O-R7or NR18R19, and R7R19is as defined above.Docket No. TP388878WO1
[0086] These precursors to the instant dye compounds typically do not absorb light above 530 nm unless until the aromaticity of the ring system is restored. In these precursors R7is H, Ci-Ce alkyl, Ci-Ce carboxyalkyl, Ci-Ce sulfoalkyl, a salt of Ci-Ce carboxyalkyl, or a salt of Ci-Ce sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl. Alternatively. R7is a monovalent radical formally derived by removing a hydroxy group from a carboxylic acid, a sulfonic acid, a phosphoric acid, or a mono- or polysaccharide, such as a glycoside. In another embodiment, R7is a photolabile caging group, such as described in Haugland, MOLECULAR PROBES HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS, Sixth Ed., Chapter 19 (1996).
[0087] R10is as defined previously, and R11is H, hydroxy, CN or alkoxy having 1-6 carbons. Alternatively, R10in combination with R11forms a 5- or 6-membered spirolactone ring, or R11in combination with R12forms a 5- or 6-membered spirolactone ring, or a 5- or 6-membered sultone ring.
[0088] These precursor compounds are readily converted to the fully conjugated imaging compounds by chemical, enzymatic, or photolytic means. Typically, the colorless precursors are substituted by an -L-Rx, moiety, or are conjugated to a desired substance (Sc).Conjugates of Reactive Compounds
[0089] The instant compounds can be substituted by at least one group -L-Rx, where Rxis the reactive group that is attached to the imaging compound by a covalent linkage L. The compounds with a reactive group (Rx) can label a wide variety of organic or inorganic substances that contain or are modified to contain functional groups with suitable reactivity, resulting in chemical attachment of the conjugated substance (Sc), represented by -L-Sc.
[0090] The reactive group and functional group are typically an electrophile and a nucleophile that can generate a covalent linkage. Typically, the conjugation reaction between the reactive compound and the substance to be conjugated results in one or more atoms of the reactive group Rxto be incorporated into a new linkage L attaching the compound to the conjugated substance Sc. Selected examples of functional groups and linkages are shown in Table 2, where the reaction of an electrophilic group and a nucleophilic group yields a covalent linkage.Docket No. TP388878WO1
[0091] The covalent linkage L binds the reactive group Rxor conjugated substance Scto the compound, either directly (L is a single bond) or with a combination of stable chemical bonds, optionally including single, double, triple or aromatic carbon-carbon bonds, as well as carbon-Docket No. TP388878WO1nitrogen bonds, nitrogen-nitrogen bonds, carbon-oxygen bonds, carbon-sulfur bonds, phosphorus-oxygen bonds, and phosphorus-nitrogen bonds. L typically includes ether, thioether, carboxamide, Sulfonamide, urea, urethane or hydrazine moieties. In one embodiment, the covalent linkage incorporates a platinum atom, such as described in U. S. Pat. No. 5,714,327 (incorporated by reference). Preferred L. moieties have 1-20 nonhydrogen atoms Selected from the group consisting of C, N, O, P, and S; and are composed of any combination of ether, thioether, amine, ester, carboxamide, sulfonamide, hydrazide bonds and aromatic or heteroaromatic bonds. Preferably L is a combination of single carbon-carbon bonds and carboxamide or thioether bonds. The longest linear segment of the linkage L preferably contains 4-10 nonhydrogen atoms, including one or two heteroatoms. Examples of L include substituted or unsubstituted polymethylene, arylene, alkylarylene, arylenealkyl, or arylthio. In one embodiment, L contains 1-6 carbon atoms, in another, L is a thioether linkage. In yet another embodiment, L is or incorporates the formula -(CH2)a(CONH(CH2)b)z-, where a has any value from 0-5, b has any value from 1-5 and z is 0 or 1.
[0092] Typically, Rxwill react with an amine, a thiol, an alcohol, an aldehyde or a ketone. In one embodiment, Rxis an acrylamide, an activated ester of a carboxylic acid, an acyl azide, an acyl nitrile, an aldehyde, an alkyl halide, an amine, an anhydride, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, a hydrazine (including hydrazides), an imido ester, an isocyanate, an isothiocyanate, a maleimide. a phosphoramidite, a reactive platinum complex, a sulfonyl halide, or a thiol group. By “reactive platinum complex' is meant chemically reactive platinum complexes such as described in U. S. Pat. No. 5,714,327 (incorporated by reference).
[0093] Rxcan be a phosphoramidite, a succinimidyl ester of a carboxylic acid, a haloacetamide, a hydrazine, an isothiocyanate, a maleimide group, a perfluorobenzamido, or an azidoperfluorobenzamido group. More preferably, Rxis a succinimidyl ester of a carboxylic acid.
[0094] Where Rxis an activated ester of a carboxylic acid (such as a succinimidyl ester), the reactive compound can be particularly useful for preparing conjugates of proteins, polysaccharides, lipids, nucleotides, or amino modified oligonucleotides or haptens. Where Rxis a maleimide or haloacetamide, the reactive compound can be particularly useful for conjugation to thiol-containing substances. Where Rxis a hydrazide, the reactive compound can be particularly useful for conjugation to periodate-oxidized carbohydrates and glycoproteins.Docket No. TP388878WO1Where Rxis a phosphoramidite, the reactive compound is particularly useful for the preparation of conjugates of oligonucleotides.
[0095] The reactive compounds can be useful for the preparation of any conjugated substance that possess a suitable functional group for covalent attachment of the compound. Examples of particularly useful conjugates include, among others, conjugates of antigens, steroids, vitamins, drugs, haptens, metabolites, toxins, environmental pollutants, amino acids, peptides, proteins, nucleotides, oligonucleotides, nucleic acids (nucleic acid polymers), carbohydrates, lipids, ioncomplexing moieties, and non-biological polymers. In certain embodiments, the conjugated substance is an amino acid, peptide, protein, nucleotide, oligonucleotide, or nucleic acid polymer. In particular, the conjugated substance is preferably a hapten or a member of a specific binding pair. Choice of the reactive group used to attach the disclosed compound to the substance to be conjugated typically depends on the functional group on the substance to be conjugated and the type or length of covalent linkage desired. The types of functional groups typically present on the organic or inorganic substances include, but are not limited to, amines, thiols, alcohols, phenols, aldehydes, ketones, phosphates, imidazoles, hydrazines, hydroxylamines, disubstituted amines, halides, epoxides, sulfonate esters, purines, pyrimidines, carboxylic acids, or a combination of these groups. A single type of reactive site may be available on the substance (typical for polysaccharides), or a variety of sites may occur (e.g. amines, thiols, alcohols, phenols), as is typical for proteins. A given conjugated substance may be conjugated to one or more compound, as disclosed herein, which may be the same or different, or to a substance that is additionally modified by a hapten or specific binding pair member. Although some selectivity in cross -reactivity can be obtained by careful control of the reaction conditions. Selectivity of labeling is best obtained by selection of an appropriate reactive functional group.
[0096] In one embodiment, the conjugated substance (Sc) is a natural or synthetic amino acid (including those that are protected or are substituted by phosphates, carbohydrates, or Ci to C22 carboxylic acids), or is a natural or synthetic polymer of amino acids such as a peptide or protein that is optionally derivatized by a chemical protecting group. Preferred conjugates of peptides contain at least five amino acids, more preferably 5 to 36 amino acids. Preferred peptides include, but are not limited to, neuropeptides, cytokines, toxins, protease substrates, and protein kinase substrates. Preferred protein conjugates include enzymes, antibodies, lectins, glycoproteins, histones, albumins, lipoproteins, avidin, streptavidin, protein A, protein G,Docket No. TP388878WO1phycobiliproteins and other fluorescent proteins (such as green fluorescent protein), hormones, toxins and growth factors. Typically, the conjugated protein is an antibody, an antibody fragment, an avidin, a streptavidin, a toxin, a lectin, a hormone, or a growth factor. Typically, where the conjugated substance is a toxin, it is a neuropeptide or a phallotoxin, such as phalloidin. In another embodiment, the conjugated substance is a polypeptide or protein that is a substrate for an exopeptidase or an endopeptidase.
[0097] In another embodiment, the conjugated substance (Sc) is a natural or synthetic nucleic acid base, nucleoside, nucleotide or a nucleic acid polymer, including those that are protected, or modified to possess an additional linker or spacer for attachment of the imaging compounds, such as an alkynyl linkage (U. S. Pat. No. 5,047,519), an aminoallyl linkage (U. S. Pat. No. 4,711,955) or other linkage. Preferably, the conjugated nucleotide is a nucleoside triphosphate or a deoxynucleoside triphosphate or a dideoxynucleoside triphosphate.
[0098] Preferred nucleic acid polymer conjugates are labeled, single- or multi- stranded, natural or synthetic DNA or RNA, DNA or RNA oligonucleotides, or DNA / RNA hybrids, or incorporate an unusual linker Such as morpholine derivatized phosphates (AntiVirals, Inc., Corvallis OR), or peptide nucleic acids such as N-(2-aminoethyl)glycine units. When the nucleic acid is a synthetic oligonucleotide, it typically contains fewer than 50 nucleotides, more typically fewer than 25 nucleotides. Larger nucleic acid polymers are typically prepared from labeled nucleotides or oligonucleotides using oligonucleotide-primed DNA polymerization, such as by using the polymerase chain reaction or through primer extension, or by terminal-transferase catalyzed addition of a labeled nucleotide to a 3'-end of a nucleic acid polymer. Typically, the imaging compound is attached via one or more purine or pyrimidine bases through an amide, ester, ether or thioether bond; or is attached to the phosphate or carbohydrate by a bond that is an ester, thioester, amide, ether or thioether. Alternatively, the imaging compound is bound to the nucleic acid polymer by chemical post-modification, such as with platinum reagents, or using a photoactivatable molecule such as a conjugated psoralen. In one embodiment, the dye is attached to the nucleotide, oligonucleotide or nucleic acid polymer via a phosphoramidite reactive group, resulting in a phosphodiester linkage. Alternatively, a conjugate is simultaneously labeled with a hapten Such as biotin, digoxigenin, or 2,4-dinitrophenyl. Nucleotide conjugates disclosed herein are readily incorporated by a DNA polymerase.Docket No. TP388878WO1
[0099] In another embodiment, the conjugated substance (Sc) is a carbohydrate that is typically a natural or synthetic polysaccharide, such as a dextran, FICOLL, heparin, glycogen, amylopectin, mannan, inulin, starch, agarose and cellulose. The carbohydrates are optionally derivatized by protecting groups such as those used in carbohydrate synthesis. The conjugated carbohydrates are optionally further substituted by one or more luminophores, that are optionally the same or different. Alternatively, the carbohydrate is a polysaccharide that is a lipopolysaccharide. Preferred polysaccharide conjugates are dextran, starch, or FICOLL conjugates.
[0100] In another embodiment, the conjugated substance (Sc), is a lipid (typically having 6-60 carbons), including glycolipids, phospholipids, Sphingolipids, glycerides, and steroids. Where the lipid is a phospholipid, the imaging compound is preferably incorporated in the polar head group of the lipid. Alternatively, the conjugated substance is a lipid assembly, such as a liposome or a lipid droplet. Such a lipid assembly optionally comprises one or more additional luminophores.
[0101] Other conjugates of non-biological materials include conjugates of organic or inorganic polymers, polymeric films, polymeric wafers, polymeric membranes, polymeric particles, polymeric microparticles including magnetic and non-magnetic microspheres, conducting and non-conducting metals and non-metals, and glass and plastic surfaces and particles, which are optionally also conjugated to one or more luminophores, which may be the same or different. Conjugates are optionally prepared by copolymerization of a compound that contains an appropriate functionality while preparing the polymer, or by chemical modification of a polymer that contains functional groups with suitable chemical reactivity. Other types of reactions that are useful for preparing conjugates of polymers include catalyzed polymerizations or copolymerizations of alkenes, such as acrylamides, and reactions of dienes with dienophiles, transesterifications or transaminations. The compounds disclosed herein are optionally incorporated in polymers by polymerization of the monomer in the presence of the imaging compound, resulting in non-covalent entrapment of the compound within the polymer matrix. In another embodiment, the conjugated substance is a glass or silica, which may be formed into an optical fiber or other structure.
[0102] Rhodamine dyes are typically prepared by condensation of an appropriate aminophenol with various derivatives of benzoic acid, phthalic acid or phthalic anhydride or sulfobenzoic acid or its anhydride. In the case of the imaging compounds described herein, the aminophenolDocket No. TP388878WO1is typically an / V-aryl or N -heteroaryl substituted aminophenol. Useful derivatives of benzoic acid include, without limitation, phthalic anhydride, trimellitic anhydride, nitrophthallic anhydride, polyhalogenated phthallic anhydrides, o-sulfobenzoic anhydride, sulfoterephthallic acid, or benzaldehydes or aliphatic dicarboxylic acids or anhydrides such as a succinic anhydride or a glutaric anhydride. This condensation reaction occurs in the presence or absence of various acid catalysts (such as zinc chloride, p-toluenesulfonic acid, sulfuric acid, or methanesulfonic acid). An aqueous workup, typically followed by column chromatography, yields the desired xanthylium dye. If an unsymmetric rhodamine dyes is desired, the condensation can be performed using one equivalent each of the appropriate substituted or unsubstituted aminophenol with one equivalent of a different aminophenol and with one equivalent of the appropriate phthalic acid derivative or benzaldehyde (as listed above) using acid catalysis (as in Khanna et al., U. S. Patent No. 4,439,359 (1984) and Haugland et al., U. S. Patent No. 5,227,487 (1993)). The desired asymmetric rhodamine dye is separated from any unwanted symmetric dye side-product(s) using crystallization or chromatographic techniques well-known in the art.
[0103] Unsymmetric rhodamine dyes can also be constructed in a stepwise fashion: A selected aminophenol is condensed with one equivalent of the appropriate benzoic or phthalic acid derivative or benzaldehyde. The resulting benzophenone derivative is typically isolated, purified and then condensed with one equivalent of a different aminophenol, yielding the asymmetric dye.
[0104] Rhodol dyes can be prepared by condensation of one equivalent each of the appropriate substituted or unsubstituted resorcinol with one equivalent of the desired A-aryl or N-heteroaryl aminophenol and with one equivalent of the appropriate phthallic acid derivative or benzaldehyde using acid catalysis (U. S. Patent No. 5,227,487 to Haugland et al. (1993)). Aryl and heteroaryl substituted xanthylium dyes are also readily prepared by displacement of the chloro groups from 3,6-dichlorofluoran or 3,6-dichlorosulfonefluoran using an appropriately substituted amine (Equation 1; U. S Patent No. 4,258,118 and German Patent 24 60491). 5- carboxy-3,6-dichlorosulfonefluoran is readily converted to a 5-carboxy-3,6-diarylamino derivative using a similar methodology.Docket No. TP388878WO1Equation 1
[0105] A variety of aryl-substituted rhodamines may be prepared using this method (Example 1). The post-condensation modification of rhodamine and rhodol dyes is well known in the chemical arts. For example, the xanthenone portion of the dye can be halogenated by treatment with the appropriate halogenating agent, such as liquid bromine. Xanthenes containing unsaturated fused rings can be hydrogenated to the saturated derivatives. The Q moieties are also subject to synthetic modification, either after the condensation reaction, or by modification of aryl and heteroaryl moieties on synthetic precursors.
[0106] When trimellitic anhydride or its derivatives is used in the dye synthesis, two isomeric carboxylates are typically formed. These isomers are separated or, in most cases, used as the mixture of isomers. The reduced derivatives of xanthylium dyes are prepared by chemical or electrochemical reduction of the xanthenone portion, such as with zinc dust or borohydride in organic solvents. Sulfonation of xanthylium dyes on the xanthene ring is typically carried out by stirring the dye in fuming sulfuric acid (20-30% SO3 content) or concentrated sulfuric acid at an appropriate temperature. In some cases, sulfonation on aryl or heteroaryl moieties is possible under these conditions.
[0107] The selection of an appropriate polyhalogenated phthallic acid derivative or benzaldehyde in the condensation of the xanthylium dye results in a dye having a di-, tri-, tetra-or pentachlorinated or di-, tri-, tetra- or pentafluorinated phenyl ring at the 9-position. Some of these polyhaloaryl substituted dyes have been shown to react with thiols via a displacement reaction, and thereby provide a facile method of introducing additional reactive groups (Gee, et al. TET. LETT. 37, 7905 (1996)).
[0108] The reduced (e.g. dihydrorhodamine) and oxidized versions of the dyes described herien are freely interconvertible by well-known oxidation or reduction reagents, including borohydrides, aluminum hydrides, hydrogen / catalyst, and dithionites. A variety of oxidizing agents mediate the oxidation of dihydrorhodamines, including molecular oxygen in theDocket No. TP388878WO1presence or absence of a catalyst, nitric oxide, peroxynitrite, dichromate, triphenylcarbenium and chloranil. The dihydrorhodamines are also oxidized by enzyme action, including horseradish peroxidase in combination with peroxides or by nitric oxide.
[0109] In general, the preparation of dye conjugates using reactive dyes is well documented, e.g. by R. Haugland, MOLECULAR PROBES HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS, Chapters 1-3 (1996); Brinkley, BIOCONJUGATE CHEM., 3, 2 (1992); Haugland, " Coupling of Monoclonal Antibodies with Fluorophores", METH. MOL. BIOL. Vol. 45, 205). Conjugates typically result from mixing appropriate reactive dyes and the substance to be conjugated in a suitable solvent in which both are soluble. For those reactive dyes that are photoactivated, conjugation requires illumination of the reaction mixture to activate the reactive dye.
[0110] By selection of the appropriate reactive functional group, substances having free amine, thiol, aldehyde or ketone groups are readily coupled to the imaging compounds by means well known in the art, as described below:
[0111] A 5-40 fold molar excess of a succinimidyl ester derivative (such as Compound 5, 8, 11, 13, 24, or 26) may be coupled to an aliphatic amine-modified nucleotide or oligonucleotide in a pH 8.3 buffer (borate or bicarbonate buffer) for greater than 1 hour. The products are purified by HPLC and characterized by their absorption spectra. Succinimidyl ester derivatives may also be coupled to amine-containing peptides or proteins, or to amino saccharides or polysaccharides in a suitable buffer such as borate or bicarbonate buffer and purified either by HPLC or size exclusion chromatography. Conjugates are characterized for their degree of substitution by spectroscopic methods.
[0112] Thiolated biomolecules are typically conjugated to thiol-reactive dyes such as Compound 22 at a pH less than 8. Aldehyde- or ketone-containing molecules are typically modified by an amine-, hydrazine- or hydroxylamine-containing dye (for example Compounds 21 and 30). sometimes followed by chemical reduction of the resulting imine, such as by a borohydride. Low molecular weight molecules are typically prepared in an organic solvent or water, purified chromatographically and characterized for purity by HPLC.
[0113] Compounds disclosed herein can be advantageously implemented in various biological applications that capitalize on their unique combination of optical properties, such as low quantum yield and high molar absorptivity in the visible to near-IR spectral region. In particular, the disclosed compounds can be implemented in various types of optical andDocket No. TP388878WO1ultrasound imaging applications, such as photoacoustic imaging (also referred to as optoacoustic imaging), photoacoustic flow cytometry, computed tomography, microscopy, artwork diagnostics, and multi-component trace gas detection.
[0114] Compounds of the present disclosure can be used for visualization of lymphatic vessels and nodes and blood vessels, for the detection and characterization of tumors, and for tracking the migration and localization of stem cells. Photoacoustic imaging compounds disclosed herein also can be used to enable functional measurements, such as oxygen saturation, total hemoglobin, distribution of biomarkers, and the like. The instant compounds can be particularly suited for use as photoacoustic contrast agents for imaging of tissues in that they can absorb light energy in the near-IR spectral region and emit acoustic signal with no loss of energy through fluorescence for maximal tissue penetration.
[0115] A general method of imaging a sample using an imaging agent, as disclosed herein, can include:a) contacting the sample with the imaging compound;b) generating an acoustic signal within the sample by exciting the compound with an energy source; andc) detecting the acoustic signal.
[0116] An exemplary photoacoustic biomedical imaging process involves contacting a site (e.g., a test site in a test subject) with a photoacoustic imaging contrast agent, as described herein, and then irradiating the contrast agent with excitation energy using an excitation light source. An example of a light source for irradiating the contrast agent includes pulsed laser or LED light. For example, the vicinity of the test site that contains the compound can be subjected to pulsed laser excitation (e.g., through a laser-generated radio-frequency pulse) using a photoacoustic imaging instrument. Various commercially available imaging systems can be used for performing the method disclosed herein, including, the transducer-array-based photoacoustic medical imaging available from iThera, FUJIFILM, VisualSonics. TomoWave Laboratories, ENDRA Life Sciences, Canon, Cyberdyne, and Seno Medical instruments.Typically, radio frequency (RF) and optical waves are used in photoacoustic imaging due to their desirable physical properties, such as deeper tissue penetration and better absorption by contrast agents, which leads to higher spatial resolution as compared to mostDocket No. TP388878WO1optical imaging techniques. Upon excitation, the contrast agent absorbs energy and consequently undergoes a thermal expansion to produce acoustic waves. The imaging process can further include generating an image from the detected acoustic signal and displaying an image of the sample in the vicinity where the contrast agent is located.
[0117] In certain embodiments, the disclosed compounds are used in a dual-modality or correlative imaging workflow in which a fluorescence image and a photoacoustic image are acquired from the same sample, tissue, or subject. The fluorescence image may be obtained before, during, or after photoacoustic interrogation. In certain embodiments, the fluorescence image is used to identify a region of interest, confirm compound delivery, assess retention after washing or clearance, or correlate superficial optical signal with deeper acoustic signal.
[0118] In certain embodiments, fluorescence detection is performed by wide-field fluorescence imaging, fluorescence microscopy, confocal microscopy, endoscopic fluorescence imaging, arthroscopic fluorescence imaging, fluorescence molecular tomography, or combinations thereof. In certain embodiments, the fluorescence image and the photoacoustic image are compared or co-registered to assess tissue localization, cartilage association, cartilage-bone interfaces, or retention of the compound in a cartilage-containing region.
[0119] To prepare a sample for photoacoustic imaging, the sample can treated with an imaging agent described in the present disclosure using various methods. In certain methods, the imaging agent can be bound to the sample for targeted studies. For injection of a contrast agent into a sample (e.g., an organ or whole animal), the imaging agent can be prepared in a suitable solution for injection, typically diluted in PBS or saline, and can be optionally filtered to remove any particulate matter.
[0120] In certain embodiments, the composition is formulated for topical administration, soaking, staining, perfusion, lavage, irrigation, local injection, intra-articular injection, periarticular injection, intraosseous delivery, intravenous injection, intra-arterial injection, subcutaneous administration, intramuscular administration, intraperitoneal administration, or combinations thereof. In certain embodiments, the composition is sterile, isotonic, and pharmaceutically acceptable. In certain embodiments, the composition further comprises one or more buffers, salts, tonicity agents, stabilizers, sugars, surfactants, proteins, polymers, carriers, liposomes, micelles, nanoparticles, hydrogels, depot-forming excipients, or combinations thereof. In certain embodiments, the composition is provided as a liquid, concentrate, lyophilizate, reconstitutable solid, or prefilled administration format.Docket No. TP388878WO1
[0121] Provided herein are compositions for injection of an imaging agent, as disclosed herein, into a sample. The concentration of the solution can be optimized based on the desired absorption characteristics and the sensitivity of the photoacoustic system. The concentration can be adjusted to ensure the concentration falls within the linear range of the photoacoustic signal response to avoid saturation or low signal-to-noise ratios. Typically, concentrations range from about 1 to 100 pM. For in vivo use, it can be advantageous to use the lowest effective concentration that provides a clear photoacoustic signal. Typically used at concentrations between 10 to 50 pM for in vivo imaging. Once the imaging compound is fully dissolved, the solution can be filtered to remove any undissolved material, ensuring a homogeneous solution. For biological applications, including those conducted in vitro or in vivo, the solution including the imaging compound can be further diluted with a biocompatible buffer, such as phosphate-buffered saline (PBS), to achieve the desired concentration. It can be desirable to store the prepared solution in a dark, cool place to prevent degradation and preserve its photoacoustic properties until use.
[0122] In certain embodiments, the compound used in the method exhibits an optical property selected from: a) a molar extinction coefficient of at least 50,000 M-1cm-1or greater; b) a quantum yield of less than about 10%; and c) absorbance of about 530 nm or greater, and a combination thereof. In some methods, the compound exhibits substantially no or minimal fluorescence when excited by the energy source.
[0123] Photoacoustic imaging can be conducted on a sample or test subject in vitro or in vivo. PAI can be used to image various types of biological and non-biological substances, including without limitation, cells, cell structures, and tissues, including synthetic versions and variants thereof (e.g., cell mimics), and the like. The sample can be any substance containing, or presumed to contain, one or more biomolecules (e.g., one or more nucleic acid and / or protein target molecules) and can include one or more of cells, a tissue or a fluid extracted and / or isolated from a subject or subjects. The sample can be derived from part of an animal or a whole animal. Samples may be derived from a mammalian or non-mammalian organism (e.g., including but not limited to a plant, virus, bacteriophage, bacteria, and / or fungus). In certain embodiments, the sample is from a mammal, such as a mouse, rat, or human. In other embodiments, the sample can be taken from an artwork (e.g., manuscript, glass or plastic art object, or a stone sculpture.) A sample may be a crude sample that has not undergone any additional sample preparation or isolation. The sample may be a processed sample that hadDocket No. TP388878WO1undergone additional processing steps to further isolate the analyte(s) of interest and / or clean up other debris or contaminants from the sample.
[0124] In some embodiments, compounds or conjugates thereof can be used to image a location in a test subject (e.g., an animal or human), such as the abdominal cavity, heart, gastrointestinal tract, pancreas, gallbladder, spleen, lymph node, liver, kidney, or eye.Depending on the imaging application, it can be desirable that the compound includes a reactive functional group capable of binding covalently to the sample. Localization of the dye at the target site can minimize diffusion of the dye into surrounding cells and tissues. When treated with a subsequent washing step, non-covalently bound components can be removed from the sample, thereby preventing aggregation of non-reacted compounds on the sample. Localization of the imaging compound on a sample also can result in lower background signal, as compared to when conventional non-targeted contrast agents are used in photoacoustic imaging applications.
[0125] For certain types of imaging methods, the imaging compound can be linked to a biologically active molecule (i.e., a molecule having an effect in a biological in vitro or in vivo system). Biologically active molecules can include growth factors, cytokines, antiseptics, antibiotics, anti-inflammatory agents, analgesics, anesthetics, chemotherapeutic agents, clotting agents, metabolites, hormones, steroids, and other drugs, or cell attachment molecules. In some embodiments, the bioactive agent can be a protein, proteinaceous molecule (e.g.. protein fragment), an antibody, an antibody fragment, an antibody like molecules, a nucleic acid, an oligonucleotide, a nucleotide or a drug. For instance, the bioactive agent may be a, such as an antibody (e.g., monoclonal or polyclonal antibody) that can bind to a target analyte at a specific determinant or epitope. The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies as well as antibody variants, fragments or antibody like molecules, such as for example. Fab. F(ab')2, scFv. Fv diabodies and linear antibodies, so long as they exhibit the desired binding activity.
[0126] In certain embodiments, the imaging compound may be used with one or more additional exogenous or endogenous absorbers. In certain embodiments, the additional absorber comprises a bone-targeted probe, vascular probe, inflammation-targeted probe, lymphatic probe, tumor-targeted probe, hemoglobin, melanin, indocyanine green, methylene blue, or combinations thereof. In certain embodiments, signals are acquired at different wavelengths and resolved by wavelength- selective excitation, spectral unmixing, subtraction, classification,Docket No. TP388878WO1segmentation, machine-learning analysis, or other multicomponent analysis to generate separate or composite maps of cartilage, bone, vasculature, synovium, inflammation, or other tissue features.
[0127] In certain embodiments, the imaging compound can be attached to a cell attachment molecule or to a group that can target a particular cell type, such as a peptide that targets cancer cells. Examples of peptide targeting ligands include, e.g., cRGD. In other embodiments, the compound can be attached to an antibody marker, such as CD133, CD44, ALDH1A1, CD34, CD24, EpCAM, and the like.
[0128] For use as a tumor contrast agent, it can be preferable to bind a high molecular compound such as a polymer or protein (e.g., albumin) to the compound to minimize the compound from being rapidly excreted from the blood before the compound accumulates in the tumor.
[0129] For certain applications, the imaging compound can be designed with a structure and / or include substituents that can specifically target a specific type of tissue. For example, by adding a quaternary ammonium group(s) to the structure of the contrast agent, the compound can target cartilage, or by adding phosphonate(s) groups to the structure, the contrast agent can target bone.
[0130] The following non-limiting examples further describe various compounds, methods, compositions, uses, and embodiments disclosed herein.EXAMPLESExample 1. Preparation of aryl-substituted rhodamine sulfonic acid compounds:
[0131] Aryl and heteroaryl substituted xanthylium dyes are readily prepared by displacement of the chloro groups from a 3.6-dichlorofluoran or a 3.6-dichlorosulfofluoran using the desired substituted amine (U. S Patent No. 4,258,118 and German Patent 2460491, both of which are incorporated by reference in their entireties), as shown in Table 2.Table 2Docket No. TP388878WO1AM3NE ISSliD WSUITiXG PRODUCTDocket No. TP388878WO1Docket No. TP388878WO1Docket No. TP388878WO1Table 3n = net determinedExample 2. Preparation of a phosphoramidite derivative (3):Docket No. TP388878WO1
[0132] Compound B of Example 1 (2 g) is heated in 20 mL of phosphorous oxychloride at 70 °C for 6 hours. The solution is evaporated under reduced pressure and the residue is dried in vacuo for several hours to yield the sulfonyl chloride derivative (Compound 1).Compound 1
[0133] The crude sulfonyl chloride thus generated is stirred in 45 mL of acetonitrile and cooled to 0 °C. To this cold solution is added a mixture of 1.2 g of 3-piperidinemethanol. 2 mL of triethylamine in 6 mL of DMF and 10 mL of acetonitrile. After one hour the acetonitrile is evaporated, the reaction mixture is poured into 1 M HC1 and extracted with chloroform.Following evaporation, the crude residue is purified on a silica gel column to yield 1.7 g of the methanol adduct 2:Compound 2
[0134] To 136 mg of 2 in 2 mL of methylene chloride at 0 °C under nitrogen is added sequentially 0.19 mL of diisopropylethylamine and 0.23 mL of 2-cyanoethyl diisopropylchlorophosphoramidite. The reaction mixture is stirred for 5 minutes then poured onto sodium bicarbonate and extracted with methylene chloride. The methylene chloride is removed under reduced pressure to yield the phosphoramidite derivative, 3.Docket No. TP388878WO1Compound 3Example 3. Preparation of a succinimidyl ester derivative (5):
[0135] Isonipecotic acid (20.5 g) is heated at reflux for 30 minutes in 80 mL of hexamethyldisilazane in the presence of a catalytic amount of concentrated sulfuric acid. Excess hexamethyldisilazane is evaporated and the residue is dissolved in 150 mL of acetonitrile and cooled to 0-5 °C. Triethylamine (23 mL) is added, followed by 29 g of the sulfonyl chloride derivative Compound 1 in 150 mL of acetonitrile to generate Compound 4, which is isolated by evaporation of the solvent, addition of 1 M HC1, extraction into chloroform and evaporation.Compound 4
[0136] To a stirring solution of Compound 4 (2.26 g) in 20 mL of acetonitrile at room temperature are added sequentially 1.1 mL of diisopropylethylamine and 1.7 g of 2-succinimido- 1, 1,3,3- tetramethyluronium tetrafluoroborate. The resulting mixture is stirred at room temperature for one hour. The solution is partitioned between CHC13 and 1 M HC1, andDocket No. TP388878WO1the organic portion is evaporated and recrystallized from CH3CN and diethyl ether to yield the desired succinimidyl ester. Compound 5.Compound 5Example 4. Preparation of a succinimidyl ester derivative (8):
[0137] Compound C (Example 1) is treated with phosphorous oxychloride and ethyl isonipecotate following the procedure of Example 2 to the ester Compound 6.Compound 6
[0138] To 0.31 g of ester 6 in 60 mL of methanol is added 1.5 mL of a 10% NaOH solution and the mixture is heated at 35-40 °C overnight. Another 2 mL of 10% NaOH is introduced and heating is continued for another 20 hours. The reaction mixture is cooled to room temperature, 120 mL of 1 M HC1 is added and after another hour the product is filtered to give product 7.Docket No. TP388878WO1Compound 7
[0139] To 98 mg of acid 7 in 1.5 mL of DMF is added 0.07 mL of diisopropylethylamine and 66 mg of 2-succinimido-l,l,3,3-tetra-methyluronium tetrafluoroborate. The reaction is worked up with chloroform and 1 M HC1 and the organic extracts are dried over magnesium sulfate. The crude material is dissolved in 2 mL of acetonitrile. Ethyl acetate (8 mL) is added dropwise and after stirring overnight the solution is filtered to yield 80 mg of product 8.Compound 8Example 5. Preparation of a succinimidyl ester derivative (11):
[0140] A mixture of 5.52 g of 3-hydroxydiphenylamine, 2.21 g of phthallic anhydride, and 2.04 g of ZnC12 is heated at 180°C for 1.5 hour. A mixture of methanol (150 mL) and water (50 mL) is added and the mixture is heated at reflux overnight. The solid is filtered and then refluxed again in 100 mL of methanol and 50 mL of water for 3 hours. The mixture is filtered to yield the acid 9.Compound 9
[0141] The carboxylic acid 9 (1.5 g) is heated at 70-75 °C in 15 mL of phosphorous oxychloride overnight to generate the acid chloride. Volatiles are removed under reduced pressure. The residue is dissolved in 30 mL of DMF followed by the addition of 2.4 mL ofDocket No. TP388878WO1triethylamine and 2.37 g of ethyl isonipecotate. After several hours at room temperature, the DMF is removed and the residue is dissolved in 30 mL of chloroform and chromatographed on silica gel to yield 0.65 g of the ethyl ester 10.Compound 10
[0142] Saponification of the ether ester 10 and conversion to the succinimidyl ester as described in Example 4 yields Compound 11.Compound 11Example 6. Preparation of a succinimidyl ester (13):
[0143] To acid 4 (Example 2, 1.5 g) in 20 mL of methylene chloride is added 0.72 mL of chlorosulfonic acid, followed by 4.5 mL of acetic anhydride. The mixture is stirred at room temperature overnight and 100 mL of ether is added precipitate the crude product. Purification is by chromatography on a silica gel column eluting with 9:1 acetonitrile / water to yield 1.0 g of the pure sulfonated derivative 12.Docket No. TP388878WO1Compound 12
[0144] To 0.6 g of acid 12 in 60 mL of DMF at room temperature is added 0.48 mL of diisopropylethylamine and 0.93 g of 2-succinimido-l,l,3,3-tetramethyluronium tetrafluoroborate. The mixture is stirred for 30 minutes. Ethyl acetate (240 mL) is added. The mixture is stirred overnight and the product 13 is recovered by filtration.Compound 13Example 7. Preparation of a succinimidyl ester derivative (15):
[0145] Compound 15 is prepared from Compound 6 following the procedure of Example 6.Compound 16Example 8. Preparation of an acid derivative (18):
[0146] A mixture of 0.83 g of 5-carboxysulfonefluorescein (prepared according to methods provided in International Publication WO 97 / 39064 (1997)), 1.26 g of phosphorus pentachloride, and 2.5 mL of phosphorus oxychloride is heated at 130 °C for 2 hours. TheDocket No. TP388878WO1mixture is cooled and poured onto 80 mL of cold water and stirred for one hour. The solid is filtered and stirred in 20 mL of 5 % NaOH for 30 minutes. The solution is acidified with 20 mL of 6 M HO. The crude 5-carboxy-3,6- dichlorosulfonefluoran is filtered and purified by stirring it in 50 mL of methanol for several hours to yield 0.13 g of the dichlorosulfonefluorancarboxylic acid 17.Compound 17
[0147] The fluoran 17 (50 mg) is heated with 1 mL of N-methylaniline at 70 °C for 3 hours. Volatile components are removed at 40 °C in vacuo. The residue is dissolved in chloroform and washed with 1 M HC1 to yield the crude material, which is purified by recrystallization from chloroform / ethyl acetate to yield 35 mg of the pure acid 18.Compound 18Example 9. Preparation of an alcohol derivative (20):
[0148] Compound 20 is prepared from Compound C of Example 1 following the procedure of Example 2 via the intermediate sulfonyl chloride derivative, Compound 19.Docket No. TP388878WO1Compound 20Example 10. Preparation of a cadaverine derivative (21):
[0149] A mixture of 0.5 g of the succinimidyl ester Compound 5 (Example 3), 0.153 g of mono-(t-BOC)-cadaverine and 0.17 mL of diisopropylethylamine in 15 mL of methylene chloride is stirred at room temperature overnight. The reaction mixture is worked up with 1 M HC1 and purified on a silica gel column to yield 0.31 g of the pure t-BOC protected sulfonamide. This product is deprotected by dissolving it in 15 mL of methylene chloride and stirring overnight with 0.5 mL of 4 M HC1 in dioxane at room temperature. Following removal of volatiles under reduced pressure, the residue is stirred in 20 mL of ether to yield 0.29 g of the amine 21 as the hydrochloride salt.Compound 21Example 11. Preparation of a maleimide derivative (22):
[0150] To the succinimidyl ester Compound 5 of Example 3 (0.5 g) in 15 mL of methylene chloride at room temperature is added 0.23 mL of diisopropylethylamine, followed by 0.26 g of N-(5- aminopentylmaleimide trifluoro acetic acid salt. The solution is stirred at room temperature for 3 hours and is then worked up with 1 M HCL The crude maleimide is purified on a silica gel column to yield 0.35 g of pure product 22.Docket No. TP388878WO1Compound 22Example 12. Preparation of a succinimidyl ester derivative (24):
[0151] Compound A (Example 1) is treated according to the procedure of Example 2 using phosphorous oxychloride and ethyl isonipecotate, followed by conversion to a succinimidyl ester derivative according to the procedure of Example 4 to yield Compound 24.Compound 24Example 13. Preparation of a Ivsine derivative (25):
[0152] To 0.41 g of Compound 24 in 10 mL of DMF and 3 mL of pyridine at room temperature is added 0.57 g of a-FMOC-L-lysine hydrochloride. The mixture is stirred at room temperature for three days, followed by warming at 35 °C for 30 minutes. The solution is poured into 130 mL of cold 1 M HC1. The crude residue is filtered and dried in vacuo then purified on a silica gel column to yield 0.55 g of the a-FMOC-L-lysine 25.Compound 25Docket No. TP388878WO1Example 14. Preparation of a succinimidyl ester derivative (26):
[0153] To Compound E (Example 1) is added 2.2 equivalents of ethyldiisopropylamine, followed by 2.4 equivalents of 2-succinimido-l,l,3,3-tetramethyluronium tetrafluoroborate. The reaction mixture is stirred for 20 minutes. Three volumes of ethyl acetate are added to the reaction mixture dropwise, and the resulting solid is collected to obtain the succinimidyl ester 26.Compound 26Example 16. Preparation of a hydroxyl derivative (27):
[0154] A mixture of 0.75 g of Compound 9 (Example 11) and 7.5 mL of phosphorous oxychloride is heated at 60°C overnight to generate the corresponding acid chloride. Excess oxychloride is evaporated and the resulting residue is dried under vacuum at 40°C for 2 hours. The crude material is then dissolved in a solution of 30 mL of acetonitrile and 3 mL of DMF at room temperature. To this solution is added a mixture of 1.1 g of 6-methylaminohexanol and 1.2 mL of triethylamine in 5 mL of acetonitrile. After the reaction mixture is stirred at room temperature for 2 hours, all volatile components are removed, the resulting residue is partitioned between chloroform and 1 M HC1, and the organic layer is dried and subjected to silica gel chromatography to yield Compound 27.Compound 27Docket No. TP388878WO1Example 17. Preparation of a hydroxy derivative (28):
[0155] Compound 28 is prepared analogously to the method provided for Compound 27 (Example 16), except that Compound A of Example 1 is used instead of Compound 9.Compound 28Example 18. Preparation of a biotinylated derivative (29):
[0156] To 25 mg of Compound 5 (Example 3) in 1 mL of DMF is added 17 mg of N-(5-aminopentyl)biotinamide trifluoroacetic acid salt and 6 pL of triethylamine. After the reaction mixture is stirred for 2 hours, 6 mL of a 1 / 1 (v / v) brine and water solution is added dropwise, and the resulting sticky crude material is purified on a silica gel chromatography column to yield Compound 29.Compound 29Example 19. Preparation of a hydrazine derivative (30):
[0157] Compound 5 (Example 3) is treated with a molar excess of hydrazine hydrate in methanol solution. After reaction is complete, the desired product is precipitated by the addition of water, the solid is collected, and purified by silica gel chromatography to yield Compound 30.Docket No. TP388878WO1Compound 30Example 20. Preparation of a phospholipid derivative (31):Compound 31
[0158] To a solution of 2.5 mg (0.003 mmol) of 2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s- indacene-3-dodecanoyl)-l-hexadecanoyl-sn-glycero-3-phosphoethanolamine in 500 pL of chloroform is added 1.0 pL (0.006 mmol) of N-diisopropylethylamine followed by 2.5 mg (0.003 mmol) of Compound 5. The mixture is stirred for 16 hours, is then diluted with 15 mL of chloroform, washed with water, and evaporated. The resulting residue is purified by silica gel chromatography to give 2.0 mg of Compound 31 as a purple solid.Example 21. Preparation of a rhodol compound (32):Compound 32Docket No. TP388878WO1
[0159] To 0.405 g of 3,6-dichlorosulfofluoran in 20 mL of acetonitrile at 0°C is added 0.107 g of N- methylaniline. The mixture is warmed to room temperature and stirred overnight. The volatile components are removed under reduced pressure and 20 mL of dioxane is added, followed by 2 mL of an aqueous 10% solution of NaOH. The reaction mixture is heated at 60°C for 4 hours to generate crude Compound 32, which is isolated by acidification with HC1, followed by chromatographic purification.Example 22. Evaluation of Compound Fluorescence:
[0160] Quantum yield measurements are made by comparing the integrated fluorescence emission of the imaging compound with the integrated fluorescence of nile blue (QY = 0.23 in ethanol) at equal dye absorbance, at the excitation wavelength. The fluorescence of buffer alone is subtracted from that of the sample for each measurement. Exemplary compounds that are essentially non-fluorescent are listed in Table 4.Table 4. Spectral properties of selected imaging compounds.Relative to fluorescein in TE buffer, pH 9.0, quantum yield 0.92.Relative to quinine sulfate in 0.1 M perchloric acid, quantum yield 0.60.nd = not determinedDocket No. TP388878WO1Example 23. Ex vivo cartilage-targeted photoacoustic imaging with a quaternary ammonium- substituted QSY21 derivative (33).
[0161] An exemplary cartilage-targeted photoacoustic imaging compound was provided having the structureCompound 33
[0162] The compound comprises a QSY21-derived chromophore linked through a sulfoamide-containing linker to a quaternary ammonium moiety (" Cart-670"). The compound may be prepared by methods analogous to those described herein for converting an activated intermediate into an amide-linked derivative and purifying the resulting product by known methods such as, for example, chromatography. Additional non-limiting cartilage-targeted analogs may be prepared analogously, including analogs that differ in linker length, quaternary ammonium head group, placement of the cartilage-targeting moiety on the scaffold, or number of cationic cartilage-targeting moieties, and such analogs may be evaluated using the ex vivo staining, washing, and photoacoustic imaging methods described herein.
[0163] In certain embodiments, the quaternary ammonium-containing cartilage-targeting moiety comprises a trimethylammonium group, a triethylammonium group, a hydroxyethyl dimethylammonium group, or a cyclic quaternary ammonium group.
[0164] Fresh chicken tissue comprising cartilage and bone was employed as an ex vivo model system. In certain embodiments, the contacting step models administration of the imaging compound to a tissue or subject, and the observed localization following contacting and washing is representative of preferential localization that may occur after local or systemic administration, followed by clearance or distribution of unassociated compound. The tissue was contacted with a solution comprising Cart-670 for approximately 10 minutes at roomDocket No. TP388878WO1temperature, and subsequently washed with approximately 30 mL of phosphate buffered saline (PBS, Thermo Fisher Scientific SKU No 10010023) to remove unassociated compound. The washed tissue was then subjected to photoacoustic imaging using excitation at or near the absorbance maximum of the compound. FIG. 1 schematically illustrates the photoacoustic imaging experiment. In the figures, localization of the imaging compound is illustrated schematically using patterned or shaded regions rather than color.
[0165] Prior to binding with the dye, a control experiment was done. The results are demonstrated in FIG. 2A. The corresponding control specimen, processed under comparable conditions but lacking the cartilage-targeting compound or treated with a non-cartilagetargeting comparator, can exhibit reduced or absent localized retention at the cartilage surface. These observations are consistent with preferential association of the compound with cartilagerich tissue.
[0166] In certain embodiments, imaging is performed before contacting the compound, after contacting the compound, after one or more wash or clearance steps, and / or at multiple subsequent time points to evaluate uptake, retention, redistribution, or clearance. In certain embodiments, the detected signal is assessed qualitatively, quantitatively, or both. In certain embodiments, analysis comprises determining cartilage-to-background signal, cartilage-to-bone signal, treated-to-control signal, localization area, retention over time, or combinations thereof. In certain embodiments, the photoacoustic data are registered with ultrasound or another anatomical imaging modality to facilitate localization of cartilage-containing regions and cartilage-bone interfaces.
[0167] As demonstrated in FIG. 2B, in certain embodiments, ex vivo tissue comprising cartilage and bone is contacted with a solution comprising a cartilage-associated imaging compound, such as Cart-670, and then washed to remove unassociated compound. As shown, the treated tissue can retain localized signal at cartilage-containing regions after washing, which is represented in the figures by increased shading, stippling, or hatching at cartilagecontaining regions, while adjacent non-cartilaginous tissue exhibits comparatively less retained signal. In the illustrated specimen, retained signal is observed at the joint region containing cartilage, consistent with preferential localization of the compound to cartilage-rich tissue. These qualitative observations support that the compound remains associated with cartilage after rinse or wash steps in an amount sufficient to permit subsequent photoacoustic detection.Docket No. TP388878WO1
[0168] In certain embodiments, the retained localization occurs at cartilage surfaces, cartilagecontaining regions of a joint, or cartilage-bone interfaces, thereby enabling differentiation of cartilage from adjacent bone or non-cartilaginous tissue.
[0169] In certain embodiments, the retained localization at cartilage-containing regions is greater than localization observed in adjacent bone or non-cartilaginous tissue under comparable conditions. In certain embodiments, such preferential association may be assessed qualitatively by visual inspection or schematically represented localization, or quantitatively by comparing relative signal levels at cartilage-containing regions versus surrounding tissue.
[0170] FIG. 3 provides representative comparative schematic depictions of control and treated tissue specimens. The treated specimen exhibits increased patterned localization at cartilagecontaining regions relative to the control specimen, indicating preferential association of the imaging compound with cartilage. In certain embodiments, such comparative localization demonstrates enhanced retention of the imaging compound in cartilage relative to surrounding tissue following washing.
[0171] The gross photographs and schematic workflow are non-limiting and are provided to illustrate that cartilage-targeted imaging compounds may be evaluated in isolated cartilage, cartilage-containing explants, osteochondral tissue, whole joints, surgically exposed tissue, cadaveric tissue, animal tissue, or human tissue, and may be used before or after washing, perfusion, or clearance of unassociated compound. The observed localization may be used alone or together with photoacoustic signal detection to identify cartilage-containing regions, distinguish cartilage from adjacent tissue, and assess cartilage condition.
[0172] In the schematic depictions of FIGS. 2B and 3, patterned regions correspond to locations of retained imaging compound following washing, whereas unpatterned regions correspond to tissue regions with comparatively reduced or absent retained compound.Following the washing step, unassociated imaging compound is reduced or removed, while compound associated with cartilage-containing regions is retained to a greater extent, thereby enhancing contrast between cartilage and surrounding tissue.
[0173] Without wishing to be bound by theory, the observed enrichment is attributed at least in part to electrostatic association between the cationic quaternary ammonium moiety and anionic components of the cartilage matrix. The interaction is described herein as preferential association rather than irreversible binding.Docket No. TP388878WO1
[0174] In certain embodiments, the imaging compound preferentially associates with one or more negatively charged components of cartilage extracellular matrix, including glycosaminoglycans, proteoglycans, aggrecan, chondroitin sulfate, keratan sulfate, hyaluronan, sulfated polysaccharides, or combinations thereof. In certain embodiments, the cartilage comprises hyaline cartilage, articular cartilage, fibrocartilage, meniscal cartilage, auricular cartilage, tracheal cartilage, costal cartilage, growth plate cartilage, temporomandibular cartilage, nasal cartilage, intervertebral disc cartilage, repair cartilage, engineered cartilage, or osteochondral tissue comprising cartilage and subchondral bone.
[0175] In further embodiments, the cartilage-targeted compound is co-administered with a second photoacoustic probe having a different absorbance maximum, such as a bone-associated probe, and the signals are separated by wavelength- selective excitation and spectral unmixing to distinguish cartilage-associated signal from bone-associated signal. Non-limiting examples of such second photoacoustic probes may include, but not limited to Alexa Fluor™ 750.
[0176] In certain embodiments, the observed preferential localization is sufficient to enable identification, differentiation, or assessment of cartilage-containing regions using photoacoustic detection.Example 24. Correlative fluorescence and photoacoustic imaging of cartilage.
[0177] In certain embodiments, a cartilage-targeted imaging compound described herein is contacted with a cartilage-containing tissue sample or a joint comprising cartilage. A fluorescence image of the sample is obtained before washing and / or after washing to evaluate compound localization and retention. The sample is then subjected to photoacoustic imaging using excitation at or near the absorbance maximum of the compound. The fluorescence image and the photoacoustic image are compared to confirm localization of the compound in a cartilage-containing region and to assess preferential retention relative to surrounding tissue.
[0178] The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the embodiments. The foregoing description and Examples detail certain embodiments and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the embodiment may be practiced in many ways and should be construed in accordance with the appended claims and any equivalents thereof.Docket No. TP388878WO1
[0179] The present disclosure includes, without limitation, the following illustrative aspects, embodiments, and combinations thereof, which are provided to summarize certain features of the disclosed subject matter and are not intended to limit the scope of the invention. Any one or more aspects may be combined with any one or more other aspects, unless clearly indicated otherwise or unless the context dictates otherwise. It will be understood that the following aspects are exemplary only, that additional embodiments are described elsewhere in the present disclosure, and that the invention encompasses modifications, variations, and equivalents apparent to those of ordinary skill in the art in view of the present disclosure. This aspects section is intended to track and summarize the presently drafted claim set in aspect format for ease of reference.
[0180] Aspect 1. A photoacoustic imaging composition, comprising: (a) an aqueous solution; and (b) an imaging compound, wherein the imaging compound comprises a xanthene group, wherein the xanthene group comprises a nitrogen atom at the 3- and / or 6-position, wherein the nitrogen atom is substituted by one or more aromatic or heteroaromatic quenching moieties, Q, wherein the aqueous solution comprises the imaging compound in a concentration suitable for detection in a photoacoustic imaging system, and wherein the compound exhibits an optical property selected from: (i) a molar extinction coefficient of at least 50,000 M-lcm-1 or greater; (ii) a quantum yield of less than about 10%; and (iii) absorbance of about 530 nm or greater, and a combination thereof.
[0181] Aspect 2. The composition of Aspect 1, wherein the aqueous solution is a buffer, saline, or a combination thereof and comprises about 1 pM to about 100 pM of the imaging compound.
[0182] Aspect 3. The composition of Aspect 1, wherein the absorbance of the compound is about 650 nm or greater.
[0183] Aspect 4. The composition of Aspect 1, wherein the absorbance maximum of the compound is about 650 nm to about 900 nm.
[0184] Aspect 5. The composition of Aspect 1, wherein the quantum yield of the compound is less than about 3%.
[0185] Aspect 6. The composition of Aspect 1, wherein the molar extinction coefficient of the compound is about 50,000 M-lcm-1 to about 10,000,000 M-lcm-1.
[0186] Aspect 7. The composition of Aspect 1, wherein the imaging compound is conjugated to a substance, wherein the conjugated substance (Sc) is a biologically derived material.Docket No. TP388878WO1
[0187] Aspect 8. The composition of Aspect 7, wherein the biologically derived material is selected from a cell, tissue vessel, node, bone, and tumor.
[0188] Aspect 9. The composition of Aspect 7, wherein the conjugated substance (Sc) is a cell-targeting peptide, an antibody, or an antigen.
[0189] Aspect 10. The composition of any one of Aspects 1-3, wherein the conjugated substance (Sc) is a non-biologically derived material, optionally a cell, tissue mimic, or a solid support such as a magnetic bead or a polystyrene support.
[0190] Aspect 11. A method of imaging a sample, comprising: (a) contacting the sample with the composition of Aspect 1; (b) exciting the compound with an energy source to produce an acoustic signal within the sample; and (c) detecting the acoustic signal.
[0191] Aspect 12. A method of imaging a sample, comprising: (a) contacting the sample with an imaging compound that comprises a xanthene group, wherein the xanthene group comprises a nitrogen atom at the 3- and / or 6-position, wherein the nitrogen atom is substituted by one or more quenching moieties, Q, wherein the compound exhibits an optical property selected from: (i) a molar extinction coefficient of at least 50,000 M-lcm-1 or greater; (ii) a quantum yield of less than about 10%; and (iii) absorbance of about 530 nm or greater, and a combination thereof; (b) exciting the compound with an energy source to produce an acoustic signal within the sample; and (c) detecting the acoustic signal.
[0192] Aspect 13. The method of Aspect 11 or Aspect 12, further comprising irradiating the compound with an excitation light source to generate the acoustic signal.
[0193] Aspect 14. The method of Aspect 11 or Aspect 12, further comprising generating an image from the detected acoustic signal.
[0194] Aspect 15. The method of Aspect 14, wherein the compound exhibits minimal fluorescence when excited by the energy source.
[0195] Aspect 16. The method of Aspect 14, wherein the compound exhibits substantially no detectable fluorescence when excited by the energy source.
[0196] Aspect 17. The method of Aspect 11 or Aspect 12, wherein the method is conducted in vivo or in vitro.
[0197] Aspect 18. The composition or method of any one of the preceding Aspects, wherein the sample is a cell or cell mimic, a blood or lymphatic vessel, a lymphatic node, a tissue or tissue mimic, artwork, a whole animal, or a human.Docket No. TP388878WO1
[0198] Aspect 19. The composition or method of any one of the preceding Aspects, wherein the imaging compound is a substituted rhodol or substituted rhodamine.
[0199] Aspect 20. The composition or method of any one of the preceding Aspects, wherein the imaging compound is selected from Table 4.
[0200] Aspect 21. The composition or method of any one of the preceding Aspects, wherein the imaging compound has Formula I:wherein: R1 is H; R6 is H; R2, R3, R4 and R5 are independently H, F, Cl, Br, I, CN; or Cl -Cl 8 alkyl, or Cl -Cl 8 alkoxy, where each alkyl or alkoxy is optionally further substituted by F, Cl, Br, I, a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a C1-C6 alcohol; or — SO3X where X is H or a counterion; or R1 taken in combination with R2, or R6 taken in combination with R5 is a fused six-membered aromatic ring; R8 and R9 are independently H, C1-C6 alkyl, C1-C6 carboxy alkyl, C1-C6 sulfoalkyl, a salt of C1-C6 carboxyalkyl, or a salt of C1-C6 sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a C1-C6 alkyl; or — L — Rx; or — L — Sc; or one or more of R8 and R9 is a Q moiety; or R8 taken in combination with R9 forms a saturated 5- or 6-membered heterocycle that is optionally fused to a Q moiety and said heterocycle is optionally further substituted by methyl, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a C1-C6 alkyl, or by — L — Rx, or — L — Sc; wherein each Q moiety is 1-4 aromatic or heteroaromatic rings that is optionally substituted by halogen, cyano, sulfo, alkali or ammonium salt of sulfo, carboxy, alkali or ammonium salt of carboxy, nitro, alkyl, perfluoroalkyl, alkoxy, alkylthio, amino,Docket No. TP388878WO1monoalkylamino, dialkylamino, alkylamido; or is substituted by — L — Rx; or is substituted by — L — Sc; wherein each heteroaromatic ring in Q is a 5- or 6-membered aromatic heterocycle having 1 to 3 heteroatoms selected from the group consisting of O, N, or S in any combination; and when Q is 2-4 rings, said 2-4 rings are fused to each other; and K is O or N+R18R19; wherein R18 and R19 are independently H, C1-C6 alkyl, C1-C6 carboxyalkyl, C1-C6 sulfoalkyl, a salt of C1-C6 carboxyalkyl, or a salt of C1-C6 sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a C1-C6 alkyl; or — L — Rx; or — L — Sc; or one or more of R18 and R19 is a Q moiety; or R18 taken in combination with R19 forms a saturated heterocyclic ring that is a morpholine, a pyrazine, or a piperazine, that is optionally substituted by methyl, sulfonic acid, a salt of sulfonic acid, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a C1-C6 alkyl; or R18 taken in combination with R19 forms a saturated 5- or 6-membered heterocycle that is a piperidine, or a pyrrolidine that is optionally fused to a Q moiety, and the heterocycle is optionally further substituted by methyl, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a C1-C6 alkyl, or by — L — Rx, or — L — Sc; RIO is H, CN. a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a C1-C6 alcohol; or RIO is a saturated or unsaturated Cl -Cl 8 alkyl that is optionally substituted one or more times by F, Cl, Br, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a C1-C6 alcohol, — SO3X, amino, alkylamino, or dialkylamino, the alkyl groups of which have 1-6 carbons; or RIO has Formula II:Docket No. TP388878WO1where R12, R13, R14, R15 and R16 are independently H, F, Cl, Br, I, — SO3X, a carboxylic acid, a salt of carboxylic acid, CN. hydroxy, amino, hydrazino; or C1-C18 alkyl, C1-C18 alkoxy, C1-C18 alkylthio, C1-C18 alkanoylamino, C1-C18 alkylaminocarbonyl, C2-C36 dialkylaminocarbonyl, Cl -Cl 8 alkyloxycarbonyl, or C6-C18 arylcarboxamido, the alkyl or aryl portions of which are optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a C1-C6 alcohol, — SO3X, amino, alkylamino, dialkylamino, or alkoxy, the alkyl portions of each having 1-6 carbons; or one pair of adjacent substituents R13 and R14, R14 and R15, or R15 and R16, when taken in combination, form a fused 6-membered aromatic ring that is optionally further substituted by carboxylic acid, or a salt of carboxylic acid; or one of R12, R13, R14, R15 and R16 is — L — Rx or — L — Sc; provided that at least one of R8, R9, R18, and R19 is, or is fused to, a Q moiety; and further provided that at least one of R8, R9, R12, R13, R14, R15, R16, R18, or R19 is — L — Rx or — L — Sc; or at least one Q moiety is substituted by — L — Rx or — L — Sc; wherein L is a covalent linkage; and Rx is a reactive functional group that is a maleimide, isocyanate, isothiocyanate, a phosphoramidite, a reactive platinum complex, perfluorobenzamido, azidoperfluorobenzamido, a succinimidyl ester, a sulfosuccinimidyl ester, an alkali or alkaline earth metal salt of a sulfosuccinimidyl ester, a symmetric anhydride, a mixed anhydride of a chloroformate having 2-8 carbons, a mixed anhydride of a carboxylic acid or perfluorinated carboxylic acid having 2-8 carbons, a mixed anhydride of a sulfonic acid or fluorinated sulfonic acid having 1-8 carbons, or an ester of a phenol or a naphthol that is further substituted one or more times by nitro, sulfo, carboxy, alkali or alkaline earth metal salt of sulfo or carboxy, cyano, fluoro, chloro, or trifluoromethyl; or Rx is the adduct of a carboxylic acid and a carbodiimide having 2-14 carbons; and Sc is a conjugated substance.
[0201] Aspect 22. The compound of Aspect 21, wherein each Q moiety is a substituted or unsubstituted phenyl, naphthyl, anthracenyl, benzothiazole, benzoxazole, or benzimidazole.
[0202] Aspect 23. The compound of Aspect 21, wherein Q is an indoline or substituted indoline.
[0203] Aspect 24. The compound of Aspect 21, wherein K is N+R18R19.
[0204] Aspect 25. The compound of Aspect 21, wherein R8 taken in combination with R9 forms a saturated 5- or 6-membered heterocycle that is fused to a Q moiety, and R18 taken in combination with R19 forms a saturated 5- or 6-membered heterocycle that is fused to a Q moiety.Docket No. TP388878WO1
[0205] Aspect 26. The compound of Aspect 21, wherein R8 = R19 and R9 = R18.
[0206] Aspect 27. The compound of Aspect 21, wherein R1, R2, R5, and R6 are each H.
[0207] Aspect 28. The compound of Aspect 21, wherein R10 has Formula II:
[0208] Aspect 29. The compound of Aspect 28, wherein one of R12-R16 is — L — Rx or — L— Sc.
[0209] Aspect 30. The compound of Aspect 28, wherein R12 is — L — Rx; wherein L is selected such that — L — Rx has Formula III:Docket No. TP388878WO1
[0210] Aspect 31. The compound of Aspect 21, wherein Rx is a succinimidyl ester of a carboxylic acid, a haloacetamide, a hydrazine, an isothiocyanate, a maleimide group, or an azidoperfluorobenzamido group.
[0211] Aspect 32. The compound of Aspect 21, having Formula IV:Docket No. TP388878WO1
[0212] wherein R8 = R19 and R9 = R18; R12 is — L — Rx, or — L — Sc; and each Q moiety is a substituted or unsubstituted phenyl, naphthyl, anthracenyl, benzothiazole, benzoxazole, or benzimidazole.
[0213] Aspect 33. A kit for photoacoustic imaging of a sample, comprising: (a) the composition or compound of any one of the preceding Aspects; and (b) instructions for using the composition or compound for photoacoustic imaging of the sample.
[0214] Aspect 34. The composition of Aspect 1, wherein the imaging compound comprises a cartilage-targeting moiety.
[0215] Aspect 35. The composition of Aspect 7 or Aspect 10, wherein the conjugated substance (Sc) is a cartilage-targeting moiety.
[0216] Aspect 36. The composition of any one of Aspects 1-2, 7, or 10, wherein the conjugated substance (Sc) is a cartilage-targeting moiety.Docket No. TP388878WO1
[0217] Aspect 37. The composition of Aspect 34, wherein the imaging compound preferentially associates with cartilage relative to bone or non-cartilaginous soft tissue after contacting a biological sample.
[0218] Aspect 38. The composition of Aspect 34, wherein the composition is formulated for administration by injection.
[0219] Aspect 39. A method of imaging cartilage, the method comprising: contacting cartilage or a joint comprising cartilage with the composition of any of Aspects 34, 35, or 36; exciting the imaging compound with an energy source to produce an acoustic signal; and detecting the acoustic signal.
[0220] Aspect 40. The method of Aspect 39. wherein the cartilage is articular cartilage.
[0221] Aspect 41. The method of Aspect 39 or Aspect 40, wherein the imaging compound preferentially localizes to cartilage after administration to the sample or subject.
[0222] Aspect 42. The method of Aspect 39, further comprising assessing cartilage integrity, cartilage degeneration, cartilage thinning, or a cartilage lesion from the detected acoustic signal.
[0223] Aspect 43. The kit of Aspect 33, wherein the instructions are for photoacoustic imaging of cartilage.
[0224] Aspect 44. The compound of Aspect 21 or Aspect 28, wherein one of R12-R16 is — L — Sc, and Sc comprises a quaternary ammonium-containing cartilage-targeting moiety.
Claims
Docket No. TP388878WO1CLAIMS1. A photoacoustic imaging composition, comprising:a) an aqueous solution; andb) an imaging compound, wherein the imaging compound comprises a xanthene group, wherein the xanthene group comprises a nitrogen atom at the 3- and / or 6-position, wherein the nitrogen atom is substituted by one or more aromatic or heteroaromatic quenching moieties, Q, wherein the aqueous solution comprises the imaging compound in a concentration suitable for detection in a photoacoustic imaging system, andwherein the compound exhibits an optical property selected from:iv. a molar extinction coefficient of at least 50,000 M-1cm-1or greater;v. a quantum yield of less than about 10%; andvi. absorbance of about 530 nm or greater, and a combination thereof.
2. The composition of claim 1, wherein the aqueous solution is a buffer, saline, or a combination thereof and comprises about 1 pM to about 100 pM of the imaging compound.
3. The composition of claim 1, wherein the absorbance of the compound is about 650 nm or greater.
4. The composition of claim 1, wherein the absorbance maximum of the compound is about 650 nm to about 900 nm.
5. The composition of claim 1, wherein the quantum yield of the compound is less than about 3%.
6. The composition of claim 1, wherein the molar extinction coefficient of the compound is about 50,000 M-1cm-1to about 10,000,000 M'1.
7. The composition of claim 1, wherein the imaging compound is conjugated to a substance, wherein the conjugated substance (Sc) is a biologically derived material.
8. The compound of claim 7, wherein the biologically derived material is selected from a cell, tissue vessel, node, bone, and tumor.Docket No. TP388878WO19. The compound of claim 7, wherein the conjugated substance (Sc) is a cell-targeting peptide, an antibody, or an antigen.
10. The compound of claim 3, wherein the conjugated substance (Sc) is a non-biologically derived material (e.g., cell, tissue mimic, or a solid support such as a magnetic bead or a polystyrene support).
11. A method of imaging a sample, comprising:a) contacting the sample with the composition of claim 1;b) exciting the compound with an energy source to produce an acoustic signal within the sample; andc) detecting the acoustic signal.
12. A method of imaging a sample, comprising:a) contacting the sample with an imaging compound that comprises a xanthene group, wherein the xanthene group comprises a nitrogen atom at the 3- and / or 6-position, wherein the nitrogen atom is substituted by one or more quenching moieties, Q,wherein the compound exhibits an optical property selected from:iv. a molar extinction coefficient of at least 50,000 M-1cm-1or greater;v. a quantum yield of less than about 10%; andvi. absorbance of about 530 nm or greater, and a combination thereof;d) exciting the compound with an energy source to produce an acoustic signal within the sample; ande) detecting the acoustic signal.
13. The method of claim 11 or 12, further comprising irradiating the compound with an excitation light source to generate the acoustic signal.
14. The method of claim 11 or 12, further comprising generating an image from the detected acoustic signal.
15. The method of claim 14, wherein the compound exhibits minimal fluorescence when excited by the energy source.
16. The method of claim 14, wherein the compound exhibits substantially no detectable fluorescence when excited by the energy source.Docket No. TP388878WO117. The method of claim 11 or 12, wherein the method is conducted in vivo or in vitro.
18. The method of any one of the preceding claims, wherein the sample is a cell or cell mimic, a blood or lymphatic vessel, a lymphatic node, a tissue or tissue mimic, artwork, a whole animal, or a human.
19. The composition or method of any one of the preceding claims, wherein the imaging compound is a substituted rhodol or substituted rhodamine.
20. The composition or method of any one of the preceding claims, wherein the imaging compound is selected from Table 4.
21. The composition or method of any one of the preceding claims, wherein the imaging compound has the formula:R1is H; R6is H;R2, R3, R4and R5are independently H, F, Cl, Br, I, CN; or Ci-Cis alkyl, or Ci- Cis alkoxy,where each alkyl or alkoxy is optionally further substituted by F, Cl, Br, I, a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Cc alcohol; or — SO3X where X is H or a counterion;or R1taken in combination with R2, or R6taken in combination with R5is a fused sixmembered aromatic ring;Docket No. TP388878WO1R8and R9are independently H, Ci-Ce alkyl, Ci-Ce carboxy alkyl, Ci-Ce sulfoalkyl, a salt of Ci-C6carboxyalkyl, or a salt of Ci-Ce sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl; or — L — Rx; or — L — Sc; or one or more of R8and R9is a Q moiety; or R8taken in combination with R9forms a saturated 5- or 6-membered heterocycle that is optionally fused to a Q moiety and said heterocycle is optionally further substituted by methyl, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce alkyl, or by — L — Rx, or — L — Sc;wherein each Q moiety is 1-4 aromatic or heteroaromatic rings that is optionally substituted by halogen, cyano, sulfo, alkali or ammonium salt of sulfo, carboxy, alkali or ammonium salt of carboxy, nitro, alkyl, perfluoroalkyl, alkoxy, alkylthio, amino, monoalkylamino, dialkylamino; alkylamido; or is substituted by — L — Rx; or is substituted by — L — Sc; wherein each heteroaromatic ring in Q is a 5- or 6-membered aromatic heterocycle having 1 to 3 heteroatoms selected from the group consisting of O, N or S in any combination; and when Q is 2-4 rings, said 2-4 rings are fused to each other; andK is O or N+R18R19;wherein R18and R19are independently H, Ci-Ce alkyl, Ci-Ce carboxyalkyl, Ci-Ce sulfoalkyl, a salt of Ci-Ce carboxyalkyl, or a salt of Ci-Ce sulfoalkyl, wherein the alkyl portions are optionally substituted by amino, hydroxy, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl; or — L — Rx; or — L — Sc; or one or more of R18and R19is a Q moiety; or R18taken in combination with R19forms a saturated heterocyclic ring that is a morpholine, a pyrazine, or a piperazine, that is optionally substituted by methyl, sulfonic acid, a salt of sulfonic acid, carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-Ce alkyl; or R18taken in combination with R19forms a saturated 5- or 6-membered heterocycle that is a piperidine, or a pyrrolidine that is optionally fused to a Q moiety, and the heterocycle is optionally further substituted by methyl, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce alkyl, or by — L — Rx, or — L — Sc;R10is H, CN, a carboxylic acid, a salt of carboxylic acid, or a carboxylic acid ester of a Ci-C6alcohol; or R10is a saturated or unsaturated Ci-Cis alkyl that is optionally substituted one or more times by F, Cl, Br, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-C6alcohol, — SO3X, amino, alkylamino, or dialkylamino, the alkyl groups of which have 1-6 carbons; or R10has the formulaDocket No. TP388878WO1dependently H, F, Cl, Br, I, — SO3X, a carboxylic acid, a salt of carboxylic acid, CN, hydroxy, amino, hydrazino; or C1-C18 alkyl, Ci-Ci8 alkoxy, Ci-Cis alkylthio, Ci-Cis alkanoylamino, Ci-Cis alkylaminocarbonyl, C2-C36 dialkylaminocarbonyl, Ci-Cis alkyloxycarbonyl, or Ce-Cis arylcarboxamido, the alkyl or aryl portions of which are optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxylic acid, a salt of carboxylic acid, a carboxylic acid ester of a Ci-Ce alcohol, — SO3X, amino, alkylamino, dialkylamino or alkoxy, the alkyl portions of each having 1-6 carbons; or one pair of adjacent substituents R13and R14, R14and R15or R15and R16, when taken in combination, form a fused 6-membered aromatic ring that is optionally further substituted by carboxylic acid, or a salt of carboxylic acid; or one of R12, R13, R14, R15and R16is — L — Rxor — L— Sc;provided that at least one of R8, R9, R18, and R19is, or is fused to, a Q moiety; and further provided that at least one of R8, R9, R12, R13, R14, R15, R16, R18, or R19is — L — Rxor — L — Sc; or at least one Q moiety is substituted by — L — Rxor — L — Sc; whereinL is a covalent linkage; andRxis a reactive functional group that is a maleimide, isocyanate, isothiocyanate, a phosphoramidite, a reactive platinum complex, perfluorobenzamido, azidoperfluorobenzamido, a succinimidyl ester, a sulfosuccinimidyl ester, an alkali or alkaline earth metal salt of a sulfosuccinimidyl ester, a symmetric anhydride, a mixed anhydride of a chloroformate having 2-8 carbons, a mixed anhydride of a carboxylic acid or perfluorinated carboxylic acid having 2-8 carbons, a mixed anhydride of a sulfonic acid or fluorinated sulfonic acid having 1-8 carbons, or an ester of a phenol or a naphthol that is further substituted one or more times by nitro, sulfo, carboxy, alkali or alkaline earth metal salt of sulfo or carboxy, cyano, fluoro, chloro, orDocket No. TP388878WO1trifluoromethyl; or Rxis the adduct of a carboxylic acid and a carbodiimide having 2-14 carbons; and Scis a conjugated substance.
22. The compound of claim 21, wherein each Q moiety is a substituted or unsubstituted phenyl, naphthyl, anthracenyl, benzothiazole, benzoxazole, or benzimidazole.
23. The compound of claim 21, wherein Q is an indoline or substituted indoline.
24. The compound of claim 21, K is N+R18R19.
25. The compound of claim 21, wherein R8taken in combination with R9forms a saturated 5- or 6-membered heterocycle that is fused to a Q moiety, and R18taken in combination with R19forms a saturated 5- or 6-membered heterocycle that is fused to a Q moiety.
26. The compound of claim 21, wherein R8=R19and R9=R18.
27. The compound of claim 21, wherein R1, R2, R5, and R6are each H.
28. The compound of claim 21, wherein R10has the formula29. The compound of claim 28, wherein one of R12-R16is — L — Rxor — L — Sc.
30. The compound of claim 28, wherein R12is — L — Rx;wherein L is selected such that — L — Rxhas the formulaDocket No. TP388878WO131. The compound of claim 21, wherein Rxis a succinimidyl ester of a carboxylic acid, a haloacetamide, a hydrazine, an isothiocyanate, a maleimide group or an azidoperfluorobenzamido group.
32. The compound of claim 21, having the formulaDocket No. TP388878WO1whereinR8=R19and R9=R18;R12is — L — Rx, or — L — Sc; andeach Q moiety is a substituted or unsubstituted phenyl, naphthyl, anthracenyl, berzothiazole, benzoxazole, or benzimidazole.
33. A kit for photoacoustic imaging of a sample, comprising:c) the composition or compound of any one of the preceding claims; andd) instructions for using the composition or compounds for photoacoustic imaging of the sample.
34. The composition of claim 1, wherein the imaging compound comprises a cartilage-targeting moiety.
35. The composition of any of claims 7 or 10, wherein the conjugated substance (Sc) is a cartilage-targeting moiety.Docket No. TP388878WO136. The composition of any of claims 1-2, 7 or 10, wherein the conjugated substance (Sc) is a cartilage-targeting moiety.
37. The composition of claim 34, wherein the imaging compound preferentially associates with cartilage relative to bone or non-cartilaginous soft tissue after contacting a biological sample.
38. The composition of claim 34, wherein the composition is formulated for administration by injection.
39. A method of imaging cartilage, the method comprising:contacting cartilage or a joint comprising cartilage with the composition of any of claims 34, 35, or 36;exciting the imaging compound with an energy source to produce an acoustic signal; and detecting the acoustic signal.
40. The method of claim 39. wherein the cartilage is articular cartilage.
41. The method of any of claims 39 or 40, wherein the imaging compound preferentially localizes to cartilage after administration to the sample or subject.
42. The method of claim 39, further comprising assessing cartilage integrity, cartilage degeneration, cartilage thinning, or a cartilage lesion from the detected acoustic signal.
43. The kit for photoacoustic imaging of claim 33, wherein the instructions are for photoacoustic imaging of cartilage.
44. The compound of any of claim 21 or 28, wherein one of R12-R16is -L- Sc, and Sccomprises a quaternary ammonium-containing cartilage-targeting moiety.
